NCCP DOSE BANDING TABLES

DOSE BANDING FOR SYSTEMIC ANTICANCER THERAPY (SACT)
<table>
<thead>
<tr>
<th>Version</th>
<th>Date</th>
<th>Amendment</th>
<th>Approved By</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>03/06/16</td>
<td>Version 1</td>
<td>Working Group</td>
</tr>
<tr>
<td>2</td>
<td>06/07/17</td>
<td>• Amendment to maximum variation range (%) calculation to keep in line with NCCP dose banding guidance documentation 2016&lt;br&gt;• Expansion of existing tables: Carboplatin&lt;br&gt;Cetuximab&lt;br&gt;Cyclophosphamide IVB&lt;br&gt;Cyclophosphamide infusion&lt;br&gt;Docetaxel&lt;br&gt;Doxorubicin&lt;br&gt;Epirubicin&lt;br&gt;5-Fluorouracil IVB&lt;br&gt;5-Fluorouracil Infusors&lt;br&gt;Oxaliplatin&lt;br&gt;Rituximab&lt;br&gt;• Addition of new tables: Azacitidine&lt;br&gt;Bortezomib 2.5mg/ml&lt;br&gt;Bendamustine&lt;br&gt;Cisplatin&lt;br&gt;Cytarabine 100mg/ml&lt;br&gt;Etoposide&lt;br&gt;Methotrexate 100mg/ml&lt;br&gt;Pembrolizumab&lt;br&gt;Pemetrexed&lt;br&gt;Vinorelbine</td>
<td>Working Group</td>
</tr>
</tbody>
</table>
Table of Contents

Introduction........................................................................................................................................... 4
Review And Feedback ............................................................................................................................... 4
Dose Banding Tables – Syringes For Subcutaneous Injection ............................................................... 5
  Azacitidine Subcutaneous Injection........................................................................................................ 5
  Bortezomib Subcutaneous Injection ......................................................................................................... 6
Dose Banding Tables – Syringes For Bolus Injection ........................................................................... 7
  Cyclophosphamide Syringes.................................................................................................................. 7
  Doxorubicin Syringes............................................................................................................................. 7
  Epirubicin Syringes.................................................................................................................................. 9
  5-Fluorouracil Syringes............................................................................................................................ 10
Dose Banding Tables – Infusions For Intravenous Administration..................................................... 11
  Bendamustine IV Infusion....................................................................................................................... 11
  Carboplatin IV Infusion........................................................................................................................... 12
  Cisplatin IV Infusion................................................................................................................................ 13
  Cyclophosphamide IV Infusion............................................................................................................... 14
  Cytarabine IV Infusion............................................................................................................................ 16
  Docetaxel IV Infusion.............................................................................................................................. 18
  Etoposide IV Infusion.............................................................................................................................. 19
  5-Fluorouracil IV Infusion....................................................................................................................... 20
  5-Fluorouracil Infusors............................................................................................................................ 22
  40MG/Ml Gemcitabine IV Infusion.......................................................................................................... 23
  38MG/Ml Gemcitabine IV Infusion.......................................................................................................... 24
  Irinotecan IV Infusion............................................................................................................................... 25
  Methotrexate IV Infusion.......................................................................................................................... 26
  Oxaliplatin IV Infusion.............................................................................................................................. 29
  Paclitaxel IV Infusion............................................................................................................................... 30
  Pembrolizumab IV Infusion..................................................................................................................... 31
  Pemetrexed IV Infusion............................................................................................................................ 32
  Vinorelbine IV Infusion............................................................................................................................. 33
Dose Banding Tables – Monoclonals For Intravenous Infusion............................................................. 34
  Monoclonals - Bevacizumab IV Infusion................................................................................................... 34
  Monoclonals – Rituximab IV Infusion....................................................................................................... 36
  Monoclonals - Trastuzumab IV Infusion.................................................................................................... 37
  Monoclonals – Cetuximab IV Infusion....................................................................................................... 38
Dose Banding Tables – Oral Anti-Cancer Medications:......................................................................... 39
  Capecitabine........................................................................................................................................... 39

NCCP Dose Banding Tables  Published: July 2017                                         Version: 2
Review: July 2019

This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding
Introduction
This document contains the NCCP national dose banding tables. These dose band tables have been developed in line with the NCCP Dose Banding Guidance document recommendations for dose banding calculations and have been agreed with ISMO and IHS. All dose bands contained in these tables are subject to local implementation and as deemed relevant to local practice.

These dose bands have been developed to cover the majority of potential doses to be given to patients. However, it is not expected that all these doses will be used commonly and that in fact, each site should identify the most likely doses applicable to their practice. The extreme ends of the dose band table can be applied to patient specific doses as and when they arise.

2017 updates have expanded some of the existing tables, now labelled individually as version 2. New tables have also been added in this update.

Dose rounding has been applied to some of these tables as opposed to dose banding. This is in order to facilitate the nearest measurable volume.

Dose bands exceeding the targeted +/-5% variation from prescribed dose are highlighted in red.

Review and Feedback
These dose band tables will be reviewed and updated as required. Please send any comments to oncologydrugs@cancercontrol.ie
If you wish to suggest drugs suitable for dose banding, please outline the drug and the suggested dose bands and send to oncologydrugs@cancercontrol.ie

<table>
<thead>
<tr>
<th>NCCP Dose Banding Tables</th>
<th>Published: July 2017</th>
<th>Version: 2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Review: July 2019</td>
<td></td>
</tr>
</tbody>
</table>

This information is valid only on the day of printing, for any updates please check [www.hse.ie/nccpdosebanding](http://www.hse.ie/nccpdosebanding)
DOSE BANDING TABLES – SYRINGES FOR SUBCUTANEOUS INJECTION:

AZACITIDINE SUBCUTANEOUS INJECTION (Version 1):

The dose bands used in this table are constructed based on a 25mg/ml concentration of azacitidine.

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

<table>
<thead>
<tr>
<th>Dose Range (mg)</th>
<th>Banded Dose (mg)</th>
<th>Maximum variation range (%)</th>
<th>Maximum variation range (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>73 - 77</td>
<td>75</td>
<td>2.60% (Upr)*, -2.74% (Lwr)</td>
<td>2mg (Upr), -2mg (Lwr)</td>
</tr>
<tr>
<td>78 - 82</td>
<td>80</td>
<td>2.44% (Upr)*, -2.56% (Lwr)</td>
<td>2mg (Upr), -2mg (Lwr)</td>
</tr>
<tr>
<td>83 - 87</td>
<td>85</td>
<td>2.30% (Upr)*, -2.41% (Lwr)</td>
<td>2mg (Upr), -2mg (Lwr)</td>
</tr>
<tr>
<td>88 - 92</td>
<td>90</td>
<td>2.17% (Upr)*, -2.27% (Lwr)</td>
<td>2mg (Upr), -2mg (Lwr)</td>
</tr>
<tr>
<td>93 - 97</td>
<td>95</td>
<td>2.06% (Upr)*, -2.15% (Lwr)</td>
<td>2mg (Upr), -2mg (Lwr)</td>
</tr>
<tr>
<td>98 - 105</td>
<td>100</td>
<td>4.76% (Upr)*, -2.04% (Lwr)</td>
<td>5mg (Upr), -2mg (Lwr)</td>
</tr>
<tr>
<td>106 - 115</td>
<td>110</td>
<td>4.35% (Upr)*, -3.77% (Lwr)</td>
<td>5mg (Upr), -4mg (Lwr)</td>
</tr>
<tr>
<td>116 - 125</td>
<td>120</td>
<td>4.00% (Upr)*, -3.45% (Lwr)</td>
<td>5mg (Upr), -4mg (Lwr)</td>
</tr>
<tr>
<td>126 - 135</td>
<td>130</td>
<td>3.70% (Upr)*, -3.17% (Lwr)</td>
<td>5mg (Upr), -4mg (Lwr)</td>
</tr>
<tr>
<td>136 - 145</td>
<td>140</td>
<td>3.45% (Upr)*, -2.94% (Lwr)</td>
<td>5mg (Upr), -4mg (Lwr)</td>
</tr>
<tr>
<td>146 - 157</td>
<td>150</td>
<td>4.46% (Upr)*, -2.74% (Lwr)</td>
<td>7mg (Upr), -4mg (Lwr)</td>
</tr>
<tr>
<td>158 - 172</td>
<td>165</td>
<td>4.07% (Upr)*, -4.43% (Lwr)</td>
<td>7mg (Upr), -7mg (Lwr)</td>
</tr>
<tr>
<td>173 - 189</td>
<td>180</td>
<td>4.76% (Upr)*, -4.05% (Lwr)</td>
<td>9mg (Upr), -7mg (Lwr)</td>
</tr>
<tr>
<td>190 - 212</td>
<td>200</td>
<td>5.66% (Upr)*, -5.26% (Lwr)</td>
<td>12mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>213 - 237</td>
<td>225</td>
<td>5.06% (Upr)*, -5.63% (Lwr)</td>
<td>12mg (Upr), -12mg (Lwr)</td>
</tr>
<tr>
<td>238 - 262</td>
<td>250</td>
<td>4.58% (Upr)*, 5.04% (Lwr)</td>
<td>12mg (Upr), -12mg (Lwr)</td>
</tr>
</tbody>
</table>
**BORTEZOMIB SUBCUTANEOUS INJECTION** (Version 1):

The dose bands used in this table are constructed based on a 2.5mg/ml concentration of bortezomib. Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

<table>
<thead>
<tr>
<th>Dose Range (mg)</th>
<th>Banded Dose (mg)</th>
<th>Maximum variation range (%)</th>
<th>Maximum variation range (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.43 - 1.62</td>
<td>1.5</td>
<td>7.41% (Upr) , -4.90% (Lwr)</td>
<td>0.12mg (Upr), -0.07mg (Lwr)</td>
</tr>
<tr>
<td>1.63 - 1.87</td>
<td>1.75</td>
<td>6.42% (Upr) , -7.36% (Lwr)</td>
<td>0.12mg (Upr), -0.12mg (Lwr)</td>
</tr>
<tr>
<td>1.88 - 2.12</td>
<td>2</td>
<td>5.66% (Upr) , -6.38% (Lwr)</td>
<td>0.12mg (Upr), -0.12mg (Lwr)</td>
</tr>
<tr>
<td>2.13 - 2.37</td>
<td>2.25</td>
<td>5.06% (Upr) , -5.63% (Lwr)</td>
<td>0.12mg (Upr), -0.12mg (Lwr)</td>
</tr>
<tr>
<td>2.38 - 2.62</td>
<td>2.5</td>
<td>4.58% (Upr) , -5.04% (Lwr)</td>
<td>0.12mg (Upr), -0.12mg (Lwr)</td>
</tr>
<tr>
<td>2.63 - 2.87</td>
<td>2.75</td>
<td>4.18% (Upr) , -4.56% (Lwr)</td>
<td>0.12mg (Upr), -0.12mg (Lwr)</td>
</tr>
<tr>
<td>2.88 - 3.12</td>
<td>3</td>
<td>3.85% (Upr) , -4.17% (Lwr)</td>
<td>0.12mg (Upr), -0.12mg (Lwr)</td>
</tr>
<tr>
<td>3.13 - 3.37</td>
<td>3.25</td>
<td>3.56% (Upr) , -3.83% (Lwr)</td>
<td>0.12mg (Upr), -0.12mg (Lwr)</td>
</tr>
<tr>
<td>3.38 - 3.62</td>
<td>3.5</td>
<td>3.31% (Upr) , -3.55% (Lwr)</td>
<td>0.12mg (Upr), -0.12mg (Lwr)</td>
</tr>
<tr>
<td>3.63 - 3.9</td>
<td>3.75</td>
<td>3.85% (Upr) , -3.31% (Lwr)</td>
<td>0.15mg (Upr), -0.12mg (Lwr)</td>
</tr>
</tbody>
</table>
DOSE BANDING TABLES – SYRINGES FOR BOLUS INJECTION:

**CYCLOPHOSPHAMIDE SYRINGES** (Version 2):
The dose bands used in this table are constructed based on a 20mg/ml concentration of cyclophosphamide.
Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

<table>
<thead>
<tr>
<th>Dose Range (mg)</th>
<th>Banded Dose (mg)</th>
<th>Maximum variation range (%)</th>
<th>Maximum variation range (mg)</th>
<th>Suggested Syringes</th>
</tr>
</thead>
<tbody>
<tr>
<td>380 - 429</td>
<td>400</td>
<td>6.76% (Upr)*, -5.26% (Lwr)</td>
<td>29mg (Upr), -20mg (Lwr)</td>
<td>400mg</td>
</tr>
<tr>
<td>430 - 479</td>
<td>460</td>
<td>3.97% (Upr)*, -6.98% (Lwr)</td>
<td>19mg (Upr), -30mg (Lwr)</td>
<td>200mg, 260mg</td>
</tr>
<tr>
<td>480 - 529</td>
<td>500</td>
<td>5.48% (Upr)*, -4.17% (Lwr)</td>
<td>29mg (Upr), -20mg (Lwr)</td>
<td>500mg</td>
</tr>
<tr>
<td>530 - 579</td>
<td>560</td>
<td>3.28% (Upr)*, -5.66% (Lwr)</td>
<td>19mg (Upr), -30mg (Lwr)</td>
<td>300mg, 260mg</td>
</tr>
<tr>
<td>580 - 629</td>
<td>600</td>
<td>4.61% (Upr)*, -3.45% (Lwr)</td>
<td>29mg (Upr), -20mg (Lwr)</td>
<td>300mg x 2</td>
</tr>
<tr>
<td>630 - 679</td>
<td>660</td>
<td>2.80% (Upr)*, -4.76% (Lwr)</td>
<td>19mg (Upr), -30mg (Lwr)</td>
<td>400mg, 260mg</td>
</tr>
<tr>
<td>680 - 729</td>
<td>700</td>
<td>3.98% (Upr)*, -2.94% (Lwr)</td>
<td>29mg (Upr), -20mg (Lwr)</td>
<td>400mg, 300mg</td>
</tr>
<tr>
<td>730 - 779</td>
<td>760</td>
<td>2.44% (Upr)*, -4.11% (Lwr)</td>
<td>19mg (Upr), -30mg (Lwr)</td>
<td>500mg, 260mg</td>
</tr>
<tr>
<td>780 - 829</td>
<td>800</td>
<td>3.50% (Upr)*, -2.56% (Lwr)</td>
<td>29mg (Upr), -20mg (Lwr)</td>
<td>400mg x 2</td>
</tr>
<tr>
<td>830 - 879</td>
<td>860</td>
<td>2.16% (Upr)*, -3.61% (Lwr)</td>
<td>19mg (Upr), -30mg (Lwr)</td>
<td>400mg, 200mg, 260mg</td>
</tr>
<tr>
<td>880 - 929</td>
<td>900</td>
<td>3.12% (Upr)*, -2.27% (Lwr)</td>
<td>29mg (Upr), -20mg (Lwr)</td>
<td>500mg, 400mg</td>
</tr>
<tr>
<td>930 - 979</td>
<td>960</td>
<td>1.94% (Upr)*, -3.23% (Lwr)</td>
<td>19mg (Upr), -30mg (Lwr)</td>
<td>500mg, 200mg, 260mg</td>
</tr>
<tr>
<td>980 - 1050</td>
<td>1000</td>
<td>4.76% (Upr)*, -2.04% (Lwr)</td>
<td>50mg (Upr), -49mg (Lwr)</td>
<td>1000mg</td>
</tr>
<tr>
<td>1051 - 1150</td>
<td>1100</td>
<td>4.35% (Upr)*, -4.66% (Lwr)</td>
<td>50mg (Upr), -49mg (Lwr)</td>
<td>500mg, 400mg, 200mg</td>
</tr>
<tr>
<td>1151 - 1250</td>
<td>1200</td>
<td>4.00% (Upr)*, -4.26% (Lwr)</td>
<td>50mg (Upr), -49mg (Lwr)</td>
<td>1000mg, 200mg</td>
</tr>
<tr>
<td>1251 - 1350</td>
<td>1300</td>
<td>3.70% (Upr)*, -3.92% (Lwr)</td>
<td>50mg (Upr), -49mg (Lwr)</td>
<td>1000mg, 300mg</td>
</tr>
<tr>
<td>1351 - 1450</td>
<td>1400</td>
<td>3.45% (Upr)*, -3.63% (Lwr)</td>
<td>50mg (Upr), -49mg (Lwr)</td>
<td>1000mg, 400mg</td>
</tr>
<tr>
<td>1451 - 1550</td>
<td>1500</td>
<td>3.23% (Upr)*, -3.38% (Lwr)</td>
<td>50mg (Upr), -49mg (Lwr)</td>
<td>1000mg, 500mg</td>
</tr>
<tr>
<td>1551 - 1650</td>
<td>1600</td>
<td>3.03% (Upr)*, -3.16% (Lwr)</td>
<td>50mg (Upr), -49mg (Lwr)</td>
<td>1000mg, 300mg, 300mg</td>
</tr>
<tr>
<td>1651 - 1750</td>
<td>1700</td>
<td>2.88% (Upr)*, -2.97% (Lwr)</td>
<td>50mg (Upr), -49mg (Lwr)</td>
<td>1000mg, 300mg, 400mg</td>
</tr>
<tr>
<td>1751 - 1850</td>
<td>1800</td>
<td>2.70% (Upr)*, -2.80% (Lwr)</td>
<td>50mg (Upr), -49mg (Lwr)</td>
<td>1000mg, 400mg, 400mg</td>
</tr>
<tr>
<td>1851 - 1950</td>
<td>1900</td>
<td>2.56% (Upr)*, -2.65% (Lwr)</td>
<td>50mg (Upr), -49mg (Lwr)</td>
<td>1000mg, 500mg, 400mg</td>
</tr>
</tbody>
</table>

Suggested Stock Syringe Sizes: 200mg, 260mg, 300mg, 400mg, 500mg, 1000mg

**DOXORUBICIN SYRINGES** (Version 2);

<table>
<thead>
<tr>
<th>NCCP Dose Banding Tables</th>
<th>Published: July 2017</th>
<th>Review: July 2019</th>
<th>Version: 2</th>
</tr>
</thead>
</table>

This information is valid only on the day of printing, for any updates please check [www.hse.ie/nccpdosebanding](http://www.hse.ie/nccpdosebanding)
The dose bands used in this table are constructed based on a 2mg/ml concentration of doxorubicin. Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

<table>
<thead>
<tr>
<th>Dose Range (mg)</th>
<th>Banded Dose (mg)</th>
<th>Maximum variation range (%)</th>
<th>Maximum variation range (mg)</th>
<th>Suggested Syringes</th>
</tr>
</thead>
<tbody>
<tr>
<td>31 - 33</td>
<td>32</td>
<td>3.03% (Upr)°, -3.23% (Lwr)°</td>
<td>1mg (Upr), -1mg (Lwr)°</td>
<td></td>
</tr>
<tr>
<td>34 - 37</td>
<td>36</td>
<td>2.70% (Upr)°, -5.88% (Lwr)°</td>
<td>1mg (Upr), -2mg (Lwr)°</td>
<td></td>
</tr>
<tr>
<td>38 - 42</td>
<td>40</td>
<td>4.76% (Upr)°, -5.26% (Lwr)°</td>
<td>2mg (Upr), -2mg (Lwr)°</td>
<td>40mg</td>
</tr>
<tr>
<td>43 - 48</td>
<td>46</td>
<td>4.17% (Upr)°, -6.98% (Lwr)°</td>
<td>2mg (Upr), -3mg (Lwr)°</td>
<td>20mg, 26mg</td>
</tr>
<tr>
<td>49 - 53</td>
<td>50</td>
<td>5.66% (Upr)°, -2.04% (Lwr)°</td>
<td>3mg (Upr), -1mg (Lwr)°</td>
<td>50mg</td>
</tr>
<tr>
<td>54 - 58</td>
<td>56</td>
<td>3.45% (Upr)°, -3.70% (Lwr)°</td>
<td>2mg (Upr), -2mg (Lwr)°</td>
<td>30mg, 26mg</td>
</tr>
<tr>
<td>59 - 63</td>
<td>60</td>
<td>4.76% (Upr)°, -1.69% (Lwr)°</td>
<td>3mg (Upr), -1mg (Lwr)°</td>
<td>30mg x 2</td>
</tr>
<tr>
<td>64 - 68</td>
<td>66</td>
<td>2.94% (Upr)°, -3.13% (Lwr)°</td>
<td>2mg (Upr), -2mg (Lwr)°</td>
<td>40mg, 26mg</td>
</tr>
<tr>
<td>69 - 73</td>
<td>70</td>
<td>4.11% (Upr)°, -1.45% (Lwr)°</td>
<td>3mg (Upr), -1mg (Lwr)°</td>
<td>40mg, 30mg</td>
</tr>
<tr>
<td>74 - 78</td>
<td>76</td>
<td>2.56% (Upr)°, -2.70% (Lwr)°</td>
<td>2mg (Upr), -2mg (Lwr)°</td>
<td>50mg, 26mg</td>
</tr>
<tr>
<td>79 - 83</td>
<td>80</td>
<td>3.61% (Upr)°, -1.27% (Lwr)°</td>
<td>3mg (Upr), -1mg (Lwr)°</td>
<td>50mg, 30mg</td>
</tr>
<tr>
<td>84 - 88</td>
<td>86</td>
<td>2.27% (Upr)°, -2.38% (Lwr)°</td>
<td>2mg (Upr), -2mg (Lwr)°</td>
<td>40mg, 20mg, 26mg</td>
</tr>
<tr>
<td>89 - 93</td>
<td>90</td>
<td>3.23% (Upr)°, -1.12% (Lwr)°</td>
<td>3mg (Upr), -1mg (Lwr)°</td>
<td>40mg, 50mg</td>
</tr>
<tr>
<td>94 - 97</td>
<td>96</td>
<td>1.03% (Upr)°, -2.13% (Lwr)°</td>
<td>1mg (Upr), -2mg (Lwr)°</td>
<td>50mg, 20mg, 26mg</td>
</tr>
<tr>
<td>98 - 105</td>
<td>100</td>
<td>4.76% (Upr)°, -2.04% (Lwr)°</td>
<td>5mg (Upr), -2mg (Lwr)°</td>
<td>100mg</td>
</tr>
<tr>
<td>106 - 115</td>
<td>110</td>
<td>4.35% (Upr)°, -3.77% (Lwr)°</td>
<td>5mg (Upr), -4mg (Lwr)°</td>
<td>50mg, 40mg, 20mg</td>
</tr>
<tr>
<td>116 - 125</td>
<td>120</td>
<td>4.00% (Upr)°, -3.45% (Lwr)°</td>
<td>5mg (Upr), -4mg (Lwr)°</td>
<td>100mg, 20mg</td>
</tr>
<tr>
<td>126 - 135</td>
<td>130</td>
<td>3.70% (Upr)°, -3.17% (Lwr)°</td>
<td>5mg (Upr), -4mg (Lwr)°</td>
<td>100mg, 30mg</td>
</tr>
<tr>
<td>136 - 145</td>
<td>140</td>
<td>3.45% (Upr)°, -2.94% (Lwr)°</td>
<td>5mg (Upr), -4mg (Lwr)°</td>
<td>100mg, 40mg</td>
</tr>
<tr>
<td>146 - 155</td>
<td>150</td>
<td>3.23% (Upr)°, -2.74% (Lwr)°</td>
<td>5mg (Upr), -4mg (Lwr)°</td>
<td>100mg, 50mg</td>
</tr>
<tr>
<td>156 - 165</td>
<td>160</td>
<td>3.03% (Upr)°, -2.56% (Lwr)°</td>
<td>5mg (Upr), -4mg (Lwr)°</td>
<td>100mg, 30mg x 2</td>
</tr>
<tr>
<td>166 - 175</td>
<td>170</td>
<td>2.86% (Upr)°, -2.41% (Lwr)°</td>
<td>5mg (Upr), -4mg (Lwr)°</td>
<td>100mg, 40mg, 30mg</td>
</tr>
<tr>
<td>176 - 185</td>
<td>180</td>
<td>2.70% (Upr)°, -2.27% (Lwr)°</td>
<td>5mg (Upr), -4mg (Lwr)°</td>
<td>100mg, 400mg x 2</td>
</tr>
<tr>
<td>186 - 195</td>
<td>190</td>
<td>2.56% (Upr)°, -2.15% (Lwr)°</td>
<td>5mg (Upr), -4mg (Lwr)°</td>
<td>100mg, 50mg, 40mg</td>
</tr>
<tr>
<td>196 - 210</td>
<td>200</td>
<td>4.76% (Upr)°, -2.04% (Lwr)°</td>
<td>10mg (Upr), -4mg (Lwr)°</td>
<td>100mg x 2</td>
</tr>
<tr>
<td>211 - 230</td>
<td>220</td>
<td>4.35% (Upr)°, -4.27% (Lwr)°</td>
<td>10mg (Upr), -9mg (Lwr)°</td>
<td>100mg x 2, 20mg x 1</td>
</tr>
<tr>
<td>231 - 250</td>
<td>240</td>
<td>4.00% (Upr)°, -3.90% (Lwr)°</td>
<td>10mg (Upr), -9mg (Lwr)°</td>
<td>100mg x 2, 40mg x 1</td>
</tr>
</tbody>
</table>

Suggested Stock Syringe Sizes: 20mg, 26mg, 30mg, 40mg, 50mg, 100mg

---

NCCP Dose Banding Tables  | Published: July 2017  | Version: 2
Review: July 2019

This information is valid only on the day of printing, for any updates please check [www.hse.ie/nccpdosebanding](http://www.hse.ie/nccpdosebanding)
**EPIRUBICIN SYRINGES (Version 2):**

The dose bands used in this table are constructed based on a 2mg/ml concentration of epirubicin. Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

<table>
<thead>
<tr>
<th>Dose Range (mg)</th>
<th>Banded Dose (mg)</th>
<th>Maximum variation range (%)</th>
<th>Maximum variation range (mg)</th>
<th>Suggested Syringes</th>
</tr>
</thead>
<tbody>
<tr>
<td>30 - 33</td>
<td>32</td>
<td>3.03% (Upr)*, 6.67% (Lwr)</td>
<td>1mg (Upr), -2mg (Lwr)</td>
<td></td>
</tr>
<tr>
<td>34 - 37</td>
<td>36</td>
<td>2.70% (Upr)*, 5.88% (Lwr)</td>
<td>1mg (Upr), -2mg (Lwr)</td>
<td></td>
</tr>
<tr>
<td>38 - 42</td>
<td>40</td>
<td>4.76% (Upr)*, 5.26% (Lwr)</td>
<td>2mg (Upr), -2mg (Lwr)</td>
<td>40mg</td>
</tr>
<tr>
<td>43 - 47</td>
<td>46</td>
<td>2.13% (Upr)*, 6.98% (Lwr)</td>
<td>1mg (Upr), -3mg (Lwr)</td>
<td>20mg, 26mg</td>
</tr>
<tr>
<td>48 - 52</td>
<td>50</td>
<td>3.85% (Upr)*, -4.17% (Lwr)</td>
<td>2mg (Upr), -2mg (Lwr)</td>
<td>50mg</td>
</tr>
<tr>
<td>53 - 57</td>
<td>56</td>
<td>1.75% (Upr)*, 5.66% (Lwr)</td>
<td>1mg (Upr), -3mg (Lwr)</td>
<td>30mg, 26mg</td>
</tr>
<tr>
<td>58 - 62</td>
<td>60</td>
<td>3.23% (Upr)*, -3.45% (Lwr)</td>
<td>2mg (Upr), -2mg (Lwr)</td>
<td>30mg x 2</td>
</tr>
<tr>
<td>63 - 67</td>
<td>66</td>
<td>1.49% (Upr)*, -4.76% (Lwr)</td>
<td>1mg (Upr), -3mg (Lwr)</td>
<td>40mg, 26mg</td>
</tr>
<tr>
<td>68 - 72</td>
<td>70</td>
<td>2.78% (Upr)*, -2.94% (Lwr)</td>
<td>2mg (Upr), -2mg (Lwr)</td>
<td>40mg, 30mg</td>
</tr>
<tr>
<td>73 - 77</td>
<td>76</td>
<td>1.30% (Upr)*, -4.11% (Lwr)</td>
<td>1mg (Upr), -3mg (Lwr)</td>
<td>50mg, 26mg</td>
</tr>
<tr>
<td>78 - 82</td>
<td>80</td>
<td>2.44% (Upr)*, -2.56% (Lwr)</td>
<td>2mg (Upr), -2mg (Lwr)</td>
<td>50mg, 30mg</td>
</tr>
<tr>
<td>83 - 87</td>
<td>86</td>
<td>1.15% (Upr)*, -3.61% (Lwr)</td>
<td>1mg (Upr), -3mg (Lwr)</td>
<td>40mg, 20mg, 26mg</td>
</tr>
<tr>
<td>88 - 92</td>
<td>90</td>
<td>2.17% (Upr)*, -2.27% (Lwr)</td>
<td>2mg (Upr), -2mg (Lwr)</td>
<td>40mg, 50mg</td>
</tr>
<tr>
<td>93 - 97</td>
<td>96</td>
<td>1.03% (Upr)*, -3.23% (Lwr)</td>
<td>1mg (Upr), -3mg (Lwr)</td>
<td>50mg, 20mg, 26mg</td>
</tr>
<tr>
<td>98 - 105</td>
<td>100</td>
<td>4.76% (Upr)*, -2.04% (Lwr)</td>
<td>5mg (Upr), -2mg (Lwr)</td>
<td>100mg</td>
</tr>
<tr>
<td>106 - 115</td>
<td>110</td>
<td>4.35% (Upr)*, -3.77% (Lwr)</td>
<td>5mg (Upr), -4mg (Lwr)</td>
<td>50mg, 40mg, 20mg</td>
</tr>
<tr>
<td>116 - 125</td>
<td>120</td>
<td>4.00% (Upr)*, -3.45% (Lwr)</td>
<td>5mg (Upr), -4mg (Lwr)</td>
<td>100mg, 20mg</td>
</tr>
<tr>
<td>126 - 135</td>
<td>130</td>
<td>3.70% (Upr)*, -3.17% (Lwr)</td>
<td>5mg (Upr), -4mg (Lwr)</td>
<td>100mg, 30mg</td>
</tr>
<tr>
<td>136 - 145</td>
<td>140</td>
<td>3.45% (Upr)*, -2.94% (Lwr)</td>
<td>5mg (Upr), -4mg (Lwr)</td>
<td>100mg, 40mg</td>
</tr>
<tr>
<td>146 - 155</td>
<td>150</td>
<td>3.23% (Upr)*, -2.74% (Lwr)</td>
<td>5mg (Upr), -4mg (Lwr)</td>
<td>100mg, 50mg</td>
</tr>
<tr>
<td>156 - 165</td>
<td>160</td>
<td>3.03% (Upr)*, -2.56% (Lwr)</td>
<td>5mg (Upr), -4mg (Lwr)</td>
<td>100mg, 30mg x 2</td>
</tr>
<tr>
<td>166 - 175</td>
<td>170</td>
<td>2.86% (Upr)*, -2.41% (Lwr)</td>
<td>5mg (Upr), -4mg (Lwr)</td>
<td>100mg, 40mg, 30mg</td>
</tr>
<tr>
<td>176 - 185</td>
<td>180</td>
<td>2.70% (Upr)*, -2.27% (Lwr)</td>
<td>5mg (Upr), -4mg (Lwr)</td>
<td>100mg, 40mg x 2</td>
</tr>
<tr>
<td>186 - 195</td>
<td>190</td>
<td>2.56% (Upr)*, -2.15% (Lwr)</td>
<td>5mg (Upr), -4mg (Lwr)</td>
<td>100mg, 50mg, 40mg</td>
</tr>
<tr>
<td>196 - 210</td>
<td>200</td>
<td>4.76% (Upr)*, -2.04% (Lwr)</td>
<td>10mg (Upr), -4mg (Lwr)</td>
<td>100mg x 2</td>
</tr>
<tr>
<td>211 - 230</td>
<td>220</td>
<td>4.35% (Upr)*, -4.27% (Lwr)</td>
<td>10mg (Upr), -9mg (Lwr)</td>
<td>100mg x 2, 20mg x 1</td>
</tr>
<tr>
<td>231 - 250</td>
<td>240</td>
<td>4.00% (Upr)*, -3.90% (Lwr)</td>
<td>10mg (Upr), -9mg (Lwr)</td>
<td>100mg x 2, 40mg x 1</td>
</tr>
</tbody>
</table>

Suggested Stock Syringe Sizes: 20mg, 26mg, 30mg, 40mg, 50mg, 100mg
**5-FLUOROURACIL SYRINGES** (Version 2):
The dose bands used in this table are constructed based on a 25mg/ml concentration of 5-fluorouracil.
Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

<table>
<thead>
<tr>
<th>Dose Range (mg)</th>
<th>Banded Dose (mg)</th>
<th>Maximum variation range (%)</th>
<th>Maximum variation range (mg)</th>
<th>Suggested Syringes</th>
</tr>
</thead>
<tbody>
<tr>
<td>238 - 262</td>
<td>250</td>
<td>4.58% (Upr)*, 5.04% (Lwr)</td>
<td>12mg (Upr), -12mg (Lwr)</td>
<td>250mg</td>
</tr>
<tr>
<td>263 - 287</td>
<td>275</td>
<td>4.18% (Upr)*, -4.56% (Lwr)</td>
<td>12mg (Upr), -12mg (Lwr)</td>
<td></td>
</tr>
<tr>
<td>288 - 312</td>
<td>300</td>
<td>3.85% (Upr)*, -4.17% (Lwr)</td>
<td>12mg (Upr), -12mg (Lwr)</td>
<td>300mg</td>
</tr>
<tr>
<td>313 - 337</td>
<td>325</td>
<td>3.56% (Upr)*, -3.83% (Lwr)</td>
<td>12mg (Upr), -12mg (Lwr)</td>
<td></td>
</tr>
<tr>
<td>338 - 362</td>
<td>350</td>
<td>3.31% (Upr)*, -3.55% (Lwr)</td>
<td>12mg (Upr), -12mg (Lwr)</td>
<td></td>
</tr>
<tr>
<td>363 - 387</td>
<td>375</td>
<td>3.10% (Upr)*, -3.31% (Lwr)</td>
<td>12mg (Upr), -12mg (Lwr)</td>
<td></td>
</tr>
<tr>
<td>388 - 424</td>
<td>400</td>
<td>5.66% (Upr)*, -3.09% (Lwr)</td>
<td>24mg (Upr), -12mg (Lwr)</td>
<td>400mg</td>
</tr>
<tr>
<td>425 - 474</td>
<td>450</td>
<td>5.06% (Upr)*, -5.88% (Lwr)</td>
<td>24mg (Upr), -25mg (Lwr)</td>
<td></td>
</tr>
<tr>
<td>475 - 525</td>
<td>500</td>
<td>4.76% (Upr)*, -5.26% (Lwr)</td>
<td>25mg (Upr), -25mg (Lwr)</td>
<td>500mg</td>
</tr>
<tr>
<td>526 - 575</td>
<td>550</td>
<td>4.35% (Upr)*, -4.56% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
<td>300mg, 250mg</td>
</tr>
<tr>
<td>576 - 625</td>
<td>600</td>
<td>4.00% (Upr)*, -4.17% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
<td>600mg</td>
</tr>
<tr>
<td>626 - 675</td>
<td>650</td>
<td>3.70% (Upr)*, -3.83% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
<td>400mg, 250mg</td>
</tr>
<tr>
<td>676 - 725</td>
<td>700</td>
<td>3.45% (Upr)*, -3.55% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
<td>400mg, 300mg</td>
</tr>
<tr>
<td>726 - 775</td>
<td>750</td>
<td>3.23% (Upr)*, -3.31% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
<td>500mg, 250mg</td>
</tr>
<tr>
<td>776 - 825</td>
<td>800</td>
<td>3.03% (Upr)*, -3.09% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
<td>400mg x 2</td>
</tr>
<tr>
<td>826 - 875</td>
<td>850</td>
<td>2.86% (Upr)*, -2.91% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
<td>600mg, 250mg</td>
</tr>
<tr>
<td>876 - 925</td>
<td>900</td>
<td>2.70% (Upr)*, -2.74% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
<td>500mg, 400mg</td>
</tr>
<tr>
<td>926 - 975</td>
<td>950</td>
<td>2.56% (Upr)*, -2.59% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
<td>400mg, 300mg, 250mg</td>
</tr>
<tr>
<td>976 - 1050</td>
<td>1000</td>
<td>2.47% (Upr)*, -2.46% (Lwr)</td>
<td>50mg (Upr), -24mg (Lwr)</td>
<td>1000mg</td>
</tr>
<tr>
<td>1051 - 1150</td>
<td>1100</td>
<td>4.35% (Upr)*, -4.66% (Lwr)</td>
<td>50mg (Upr), -49mg (Lwr)</td>
<td>500mg, 400mg, 200mg</td>
</tr>
<tr>
<td>1151 - 1250</td>
<td>1200</td>
<td>4.00% (Upr)*, -4.26% (Lwr)</td>
<td>50mg (Upr), -49mg (Lwr)</td>
<td>1000mg, 200mg</td>
</tr>
<tr>
<td>1251 - 1350</td>
<td>1300</td>
<td>3.70% (Upr)*, -3.92% (Lwr)</td>
<td>50mg (Upr), -49mg (Lwr)</td>
<td>1000mg, 300mg</td>
</tr>
<tr>
<td>1351 - 1450</td>
<td>1400</td>
<td>3.45% (Upr)*, -3.63% (Lwr)</td>
<td>50mg (Upr), -49mg (Lwr)</td>
<td>1000mg, 400mg</td>
</tr>
<tr>
<td>1451 - 1550</td>
<td>1500</td>
<td>3.23% (Upr)*, -3.38% (Lwr)</td>
<td>50mg (Upr), -49mg (Lwr)</td>
<td>1000mg, 500mg</td>
</tr>
</tbody>
</table>

Suggested Stock Syringe Sizes: 250mg, 300mg, 400mg, 500mg, 600mg, 1000mg

This information is valid only on the day of printing, for any updates please check [www.hse.ie/nccpdosebanding](http://www.hse.ie/nccpdosebanding)
**DOSE BANDING TABLES – INFUSIONS for INTRAVENOUS ADMINISTRATION:**

**BENDAMUSTINE IV INFUSION** (Version 1):
The dose bands used in this table are constructed based on a 2.5mg/ml concentration of bendamustine
Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume

<table>
<thead>
<tr>
<th>Dose Range (mg)</th>
<th>Banded Dose (mg)</th>
<th>Maximum variation range (%)</th>
<th>Maximum variation range (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>73 - 77</td>
<td>75</td>
<td>2.60% (Upr)**, -2.74% (Lwr)</td>
<td>2mg (Upr), -2mg (Lwr)</td>
</tr>
<tr>
<td>78 - 82</td>
<td>80</td>
<td>2.44% (Upr)**, -2.56% (Lwr)</td>
<td>2mg (Upr), -2mg (Lwr)</td>
</tr>
<tr>
<td>83 - 87</td>
<td>85</td>
<td>2.30% (Upr)**, -2.41% (Lwr)</td>
<td>2mg (Upr), -2mg (Lwr)</td>
</tr>
<tr>
<td>88 - 92</td>
<td>90</td>
<td>2.17% (Upr)**, -2.27% (Lwr)</td>
<td>2mg (Upr), -2mg (Lwr)</td>
</tr>
<tr>
<td>93 - 97</td>
<td>95</td>
<td>2.06% (Upr)**, -2.15% (Lwr)</td>
<td>2mg (Upr), -2mg (Lwr)</td>
</tr>
<tr>
<td>98 - 105</td>
<td>100</td>
<td>4.76% (Upr)**, -2.04% (Lwr)</td>
<td>5mg (Upr), -2mg (Lwr)</td>
</tr>
<tr>
<td>106 - 115</td>
<td>110</td>
<td>4.35% (Upr)**, -3.77% (Lwr)</td>
<td>5mg (Upr), -4mg (Lwr)</td>
</tr>
<tr>
<td>116 - 127</td>
<td>120</td>
<td>5.51% (Upr)**, -3.45% (Lwr)</td>
<td>7mg (Upr), -4mg (Lwr)</td>
</tr>
<tr>
<td>128 - 142</td>
<td>135</td>
<td>4.93% (Upr)**, -5.47% (Lwr)</td>
<td>7mg (Upr), -7mg (Lwr)</td>
</tr>
<tr>
<td>143 - 157</td>
<td>150</td>
<td>4.46% (Upr)**, -4.90% (Lwr)</td>
<td>7mg (Upr), -7mg (Lwr)</td>
</tr>
<tr>
<td>158 - 172</td>
<td>165</td>
<td>4.07% (Upr)**, -4.43% (Lwr)</td>
<td>7mg (Upr), -7mg (Lwr)</td>
</tr>
<tr>
<td>173 - 189</td>
<td>180</td>
<td>4.76% (Upr)**, -4.05% (Lwr)</td>
<td>9mg (Upr), -7mg (Lwr)</td>
</tr>
<tr>
<td>190 - 212</td>
<td>200</td>
<td>5.66% (Upr)**, -5.26% (Lwr)</td>
<td>12mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>213 - 237</td>
<td>225</td>
<td>6.66% (Upr)**, -5.63% (Lwr)</td>
<td>12mg (Upr), -12mg (Lwr)</td>
</tr>
<tr>
<td>238 - 262</td>
<td>250</td>
<td>4.58% (Upr)**, -5.04% (Lwr)</td>
<td>12mg (Upr), -12mg (Lwr)</td>
</tr>
<tr>
<td>263 - 287</td>
<td>275</td>
<td>4.18% (Upr)**, -4.56% (Lwr)</td>
<td>12mg (Upr), -12mg (Lwr)</td>
</tr>
<tr>
<td>288 - 315</td>
<td>300</td>
<td>4.76% (Upr)**, -4.17% (Lwr)</td>
<td>15mg (Upr), -12mg (Lwr)</td>
</tr>
</tbody>
</table>
CARBOPLATIN IV INFUSION (Version 2):
The dose bands used in this table are constructed based on a 10mg/ml concentration of carboplatin
Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume

<table>
<thead>
<tr>
<th>Dose Range (mg)</th>
<th>Banded Dose (mg)</th>
<th>Maximum variation range (%)</th>
<th>Maximum variation range (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>125 - 134</td>
<td>130</td>
<td>2.99% (Upr)*, -4.00% (Lwr)</td>
<td>4mg (Upr), -5mg (Lwr)</td>
</tr>
<tr>
<td>135 - 144</td>
<td>140</td>
<td>2.78% (Upr)*, -3.70% (Lwr)</td>
<td>4mg (Upr), -5mg (Lwr)</td>
</tr>
<tr>
<td>145 - 154</td>
<td>150</td>
<td>2.60% (Upr)*, -3.45% (Lwr)</td>
<td>4mg (Upr), -5mg (Lwr)</td>
</tr>
<tr>
<td>155 - 169</td>
<td>160</td>
<td>2.33% (Upr)*, -3.23% (Lwr)</td>
<td>9mg (Upr), -5mg (Lwr)</td>
</tr>
<tr>
<td>170 - 189</td>
<td>180</td>
<td>4.76% (Upr)*,  -5.88% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>190 - 209</td>
<td>200</td>
<td>4.31% (Upr)*,  -5.26% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>210 - 229</td>
<td>220</td>
<td>3.93% (Upr)*, -4.76% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>230 - 249</td>
<td>240</td>
<td>3.61% (Upr)*, -4.35% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>250 - 269</td>
<td>260</td>
<td>3.35% (Upr)*, -4.00% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>270 - 294</td>
<td>280</td>
<td>4.76% (Upr)*, -3.70% (Lwr)</td>
<td>14mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>295 - 324</td>
<td>310</td>
<td>4.32% (Upr)*, -5.08% (Lwr)</td>
<td>14mg (Upr), -15mg (Lwr)</td>
</tr>
<tr>
<td>325 - 355</td>
<td>340</td>
<td>4.23% (Upr)*, -4.62% (Lwr)</td>
<td>15mg (Upr), -15mg (Lwr)</td>
</tr>
<tr>
<td>356 - 385</td>
<td>370</td>
<td>3.90% (Upr)*, -3.93% (Lwr)</td>
<td>15mg (Upr), -14mg (Lwr)</td>
</tr>
<tr>
<td>386 - 420</td>
<td>400</td>
<td>4.76% (Upr)*, -3.63% (Lwr)</td>
<td>20mg (Upr), -14mg (Lwr)</td>
</tr>
<tr>
<td>421 - 460</td>
<td>440</td>
<td>4.35% (Upr)*, -4.51% (Lwr)</td>
<td>20mg (Upr), -19mg (Lwr)</td>
</tr>
<tr>
<td>461 - 500</td>
<td>480</td>
<td>4.00% (Upr)*, -4.12% (Lwr)</td>
<td>20mg (Upr), -19mg (Lwr)</td>
</tr>
<tr>
<td>501 - 540</td>
<td>520</td>
<td>3.70% (Upr)*, -3.79% (Lwr)</td>
<td>20mg (Upr), -19mg (Lwr)</td>
</tr>
<tr>
<td>541 - 580</td>
<td>560</td>
<td>3.45% (Upr)*, -3.51% (Lwr)</td>
<td>20mg (Upr), -19mg (Lwr)</td>
</tr>
<tr>
<td>581 - 625</td>
<td>600</td>
<td>4.00% (Upr)*, -3.27% (Lwr)</td>
<td>25mg (Upr), -19mg (Lwr)</td>
</tr>
<tr>
<td>626 - 680</td>
<td>650</td>
<td>4.41% (Upr)*, -3.83% (Lwr)</td>
<td>30mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>681 - 740</td>
<td>710</td>
<td>4.05% (Upr)*, -4.26% (Lwr)</td>
<td>30mg (Upr), -29mg (Lwr)</td>
</tr>
<tr>
<td>741 - 810</td>
<td>770</td>
<td>4.94% (Upr)*, -3.91% (Lwr)</td>
<td>40mg (Upr), -29mg (Lwr)</td>
</tr>
<tr>
<td>811 - 890</td>
<td>850</td>
<td>4.49% (Upr)*, -4.81% (Lwr)</td>
<td>40mg (Upr), -39mg (Lwr)</td>
</tr>
<tr>
<td>891 - 975</td>
<td>930</td>
<td>4.62% (Upr)*, -4.38% (Lwr)</td>
<td>45mg (Upr), -39mg (Lwr)</td>
</tr>
<tr>
<td>976 - 1070</td>
<td>1020</td>
<td>4.67% (Upr)*, -4.51% (Lwr)</td>
<td>50mg (Upr), -44mg (Lwr)</td>
</tr>
<tr>
<td>1071 - 1170</td>
<td>1120</td>
<td>4.27% (Upr)*, -4.58% (Lwr)</td>
<td>50mg (Upr), -49mg (Lwr)</td>
</tr>
<tr>
<td>1171 - 1280</td>
<td>1220</td>
<td>4.69% (Upr)*, -4.18% (Lwr)</td>
<td>60mg (Upr), -49mg (Lwr)</td>
</tr>
</tbody>
</table>

This information is valid only on the day of printing, for any updates please check [www.hse.ie/nccpdosebanding](http://www.hse.ie/nccpdosebanding)
CISPLATIN IV INFUSION Version 1:
The dose bands used in this table are constructed based on a 1mg/ml concentration of cisplatin.
Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

<table>
<thead>
<tr>
<th>Dose Range (mg)</th>
<th>Banded Dose (mg)</th>
<th>Maximum variation range (%)</th>
<th>Maximum variation range (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>19 - 21</td>
<td>20</td>
<td>4.76% (Up) , 5.26% (Lwr)</td>
<td>1mg (Up), -1mg (Lwr)</td>
</tr>
<tr>
<td>22 - 24</td>
<td>23</td>
<td>4.17% (Up) , -4.55% (Lwr)</td>
<td>1mg (Up), -1mg (Lwr)</td>
</tr>
<tr>
<td>25 - 27</td>
<td>26</td>
<td>3.70% (Up) , -4.00% (Lwr)</td>
<td>1mg (Up), -1mg (Lwr)</td>
</tr>
<tr>
<td>28 - 30</td>
<td>29</td>
<td>3.33% (Up) , -3.57% (Lwr)</td>
<td>1mg (Up), -1mg (Lwr)</td>
</tr>
<tr>
<td>31 - 33</td>
<td>32</td>
<td>3.03% (Up) , -3.23% (Lwr)</td>
<td>1mg (Up), -1mg (Lwr)</td>
</tr>
<tr>
<td>34 - 37</td>
<td>35</td>
<td>5.41% (Up) , -2.94% (Lwr)</td>
<td>2mg (Up), -1mg (Lwr)</td>
</tr>
<tr>
<td>38 - 42</td>
<td>40</td>
<td>4.76% (Up) , 5.26% (Lwr)</td>
<td>2mg (Up), -2mg (Lwr)</td>
</tr>
<tr>
<td>43 - 47</td>
<td>45</td>
<td>4.26% (Up) , -4.65% (Lwr)</td>
<td>2mg (Up), -2mg (Lwr)</td>
</tr>
<tr>
<td>48 - 52</td>
<td>50</td>
<td>3.85% (Up) , -4.17% (Lwr)</td>
<td>2mg (Up), -2mg (Lwr)</td>
</tr>
<tr>
<td>53 - 57</td>
<td>55</td>
<td>3.51% (Up) , -3.77% (Lwr)</td>
<td>2mg (Up), -2mg (Lwr)</td>
</tr>
<tr>
<td>58 - 62</td>
<td>60</td>
<td>3.23% (Up) , -3.45% (Lwr)</td>
<td>2mg (Up), -2mg (Lwr)</td>
</tr>
<tr>
<td>63 - 68</td>
<td>66</td>
<td>2.94% (Up) , -4.76% (Lwr)</td>
<td>2mg (Up), -3mg (Lwr)</td>
</tr>
<tr>
<td>69 - 76</td>
<td>72</td>
<td>5.26% (Up) , -4.35% (Lwr)</td>
<td>4mg (Up), -3mg (Lwr)</td>
</tr>
<tr>
<td>77 - 84</td>
<td>80</td>
<td>4.76% (Up) , -3.90% (Lwr)</td>
<td>4mg (Up), -3mg (Lwr)</td>
</tr>
<tr>
<td>85 - 94</td>
<td>90</td>
<td>4.26% (Up) , -5.88% (Lwr)</td>
<td>4mg (Up), -5mg (Lwr)</td>
</tr>
<tr>
<td>95 - 104</td>
<td>100</td>
<td>3.85% (Up) , 5.26% (Lwr)</td>
<td>4mg (Up), -5mg (Lwr)</td>
</tr>
<tr>
<td>105 - 114</td>
<td>110</td>
<td>3.51% (Up) , -4.76% (Lwr)</td>
<td>4mg (Up), -5mg (Lwr)</td>
</tr>
<tr>
<td>115 - 124</td>
<td>120</td>
<td>3.23% (Up) , -4.35% (Lwr)</td>
<td>4mg (Up), -5mg (Lwr)</td>
</tr>
<tr>
<td>125 - 134</td>
<td>130</td>
<td>2.99% (Up) , -4.00% (Lwr)</td>
<td>4mg (Up), -5mg (Lwr)</td>
</tr>
<tr>
<td>135 - 144</td>
<td>140</td>
<td>2.78% (Up) , -3.70% (Lwr)</td>
<td>4mg (Up), -5mg (Lwr)</td>
</tr>
<tr>
<td>145 - 154</td>
<td>150</td>
<td>2.60% (Up) , -3.45% (Lwr)</td>
<td>4mg (Up), -5mg (Lwr)</td>
</tr>
<tr>
<td>155 - 169</td>
<td>160</td>
<td>2.33% (Up) , 3.23% (Lwr)</td>
<td>9mg (Up), -5mg (Lwr)</td>
</tr>
<tr>
<td>170 - 189</td>
<td>180</td>
<td>4.76% (Up) , 5.86% (Lwr)</td>
<td>9mg (Up), -10mg (Lwr)</td>
</tr>
<tr>
<td>190 - 209</td>
<td>200</td>
<td>4.31% (Up) , 5.26% (Lwr)</td>
<td>9mg (Up), -10mg (Lwr)</td>
</tr>
<tr>
<td>210 - 229</td>
<td>220</td>
<td>3.93% (Up) , -4.76% (Lwr)</td>
<td>9mg (Up), -10mg (Lwr)</td>
</tr>
<tr>
<td>230 - 249</td>
<td>240</td>
<td>3.61% (Up) , -4.35% (Lwr)</td>
<td>9mg (Up), -10mg (Lwr)</td>
</tr>
<tr>
<td>250 - 269</td>
<td>260</td>
<td>3.35% (Up) , -4.00% (Lwr)</td>
<td>9mg (Up), -10mg (Lwr)</td>
</tr>
<tr>
<td>270 - 294</td>
<td>280</td>
<td>4.76% (Up) , -3.70% (Lwr)</td>
<td>14mg (Up), -10mg (Lwr)</td>
</tr>
<tr>
<td>295 - 324</td>
<td>310</td>
<td>4.32% (Up) , -5.08% (Lwr)</td>
<td>14mg (Up), -15mg (Lwr)</td>
</tr>
</tbody>
</table>
**CYCLOPHOSPHAMIDE IV INFUSION Version 2:**
The dose bands used in this table are constructed based on a 20mg/ml concentration of cyclophosphamide.
Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

<table>
<thead>
<tr>
<th>Dose Range (mg)</th>
<th>Banded Dose (mg)</th>
<th>Maximum variation range (%)</th>
<th>Maximum variation range (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>190 - 209</td>
<td>200</td>
<td>4.31% (Upr)°, -5.26% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>210 - 229</td>
<td>220</td>
<td>3.93% (Upr)°, -4.76% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>230 - 249</td>
<td>240</td>
<td>3.61% (Upr)°, -4.35% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>250 - 269</td>
<td>260</td>
<td>3.35% (Upr)°, -4.00% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>270 - 289</td>
<td>280</td>
<td>3.11% (Upr)°, -3.70% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>290 - 309</td>
<td>300</td>
<td>2.91% (Upr)°, -3.45% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>310 - 329</td>
<td>320</td>
<td>2.74% (Upr)°, -3.23% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>330 - 349</td>
<td>340</td>
<td>2.58% (Upr)°, -3.03% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>350 - 369</td>
<td>360</td>
<td>2.44% (Upr)°, -2.86% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>370 - 399</td>
<td>380</td>
<td>2.47% (Upr)°, -2.70% (Lwr)</td>
<td>19mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>400 - 439</td>
<td>420</td>
<td>2.33% (Upr)°, -5.00% (Lwr)</td>
<td>19mg (Upr), -20mg (Lwr)</td>
</tr>
<tr>
<td>440 - 479</td>
<td>460</td>
<td>3.97% (Upr)°, -4.55% (Lwr)</td>
<td>19mg (Upr), -20mg (Lwr)</td>
</tr>
<tr>
<td>480 - 529</td>
<td>560</td>
<td>5.48% (Upr)°, -4.17% (Lwr)</td>
<td>29mg (Upr), -20mg (Lwr)</td>
</tr>
<tr>
<td>530 - 579</td>
<td>560</td>
<td>3.28% (Upr)°, -5.66% (Lwr)</td>
<td>19mg (Upr), -30mg (Lwr)</td>
</tr>
<tr>
<td>580 - 629</td>
<td>600</td>
<td>4.61% (Upr)°, -3.45% (Lwr)</td>
<td>29mg (Upr), -20mg (Lwr)</td>
</tr>
<tr>
<td>630 - 689</td>
<td>660</td>
<td>4.21% (Upr)°, -4.76% (Lwr)</td>
<td>29mg (Upr), -30mg (Lwr)</td>
</tr>
<tr>
<td>690 - 750</td>
<td>720</td>
<td>4.00% (Upr)°, -4.35% (Lwr)</td>
<td>30mg (Upr), -30mg (Lwr)</td>
</tr>
<tr>
<td>751 - 810</td>
<td>780</td>
<td>3.70% (Upr)°, -3.86% (Lwr)</td>
<td>30mg (Upr), -29mg (Lwr)</td>
</tr>
<tr>
<td>811 - 880</td>
<td>840</td>
<td>4.55% (Upr)°, -3.58% (Lwr)</td>
<td>40mg (Upr), -29mg (Lwr)</td>
</tr>
<tr>
<td>881 - 960</td>
<td>920</td>
<td>4.17% (Upr)°, -4.43% (Lwr)</td>
<td>40mg (Upr), -39mg (Lwr)</td>
</tr>
<tr>
<td>961 - 1050</td>
<td>1000</td>
<td>4.76% (Upr)°, -4.06% (Lwr)</td>
<td>50mg (Upr), -39mg (Lwr)</td>
</tr>
<tr>
<td>1051 - 1150</td>
<td>1100</td>
<td>4.35% (Upr)°, -4.66% (Lwr)</td>
<td>50mg (Upr), -49mg (Lwr)</td>
</tr>
<tr>
<td>1151 - 1250</td>
<td>1200</td>
<td>4.00% (Upr)°, -4.26% (Lwr)</td>
<td>50mg (Upr), -49mg (Lwr)</td>
</tr>
<tr>
<td>1251 - 1350</td>
<td>1300</td>
<td>3.70% (Upr)°, -3.92% (Lwr)</td>
<td>50mg (Upr), -49mg (Lwr)</td>
</tr>
<tr>
<td>1351 - 1470</td>
<td>1400</td>
<td>4.76% (Upr)°, -3.63% (Lwr)</td>
<td>70mg (Upr), -49mg (Lwr)</td>
</tr>
<tr>
<td>1471 - 1600</td>
<td>1540</td>
<td>3.75% (Upr)°, -4.69% (Lwr)</td>
<td>60mg (Upr), -69mg (Lwr)</td>
</tr>
<tr>
<td>1601 - 1740</td>
<td>1680</td>
<td>3.45% (Upr)°, -4.93% (Lwr)</td>
<td>60mg (Upr), -79mg (Lwr)</td>
</tr>
<tr>
<td>1741 - 1900</td>
<td>1820</td>
<td>4.21% (Upr)°, -4.54% (Lwr)</td>
<td>80mg (Upr), -79mg (Lwr)</td>
</tr>
<tr>
<td>Range</td>
<td>Dose (mg)</td>
<td>Upper Range (%)</td>
<td>Lower Range (%)</td>
</tr>
<tr>
<td>----------</td>
<td>-----------</td>
<td>-----------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>1901 - 2100</td>
<td>2000</td>
<td>4.76% Upr, 5.21% Lwr</td>
<td>100mg (Upr), -99mg (Lwr)</td>
</tr>
<tr>
<td>2101 - 2300</td>
<td>2200</td>
<td>4.35% Upr, -4.71% Lwr</td>
<td>100mg (Upr), -99mg (Lwr)</td>
</tr>
<tr>
<td>2301 - 2520</td>
<td>2400</td>
<td>4.76% Upr, -4.30% Lwr</td>
<td>120mg (Upr), -99mg (Lwr)</td>
</tr>
<tr>
<td>2521 - 2760</td>
<td>2640</td>
<td>4.35% Upr, -4.72% Lwr</td>
<td>120mg (Upr), -119mg (Lwr)</td>
</tr>
<tr>
<td>2761 - 3040</td>
<td>2900</td>
<td>4.61% Upr, 5.03% Lwr</td>
<td>140mg (Upr), -139mg (Lwr)</td>
</tr>
<tr>
<td>3041 - 3350</td>
<td>3200</td>
<td>4.48% Upr, 5.23% Lwr</td>
<td>150mg (Upr), -159mg (Lwr)</td>
</tr>
<tr>
<td>3351 - 3650</td>
<td>3500</td>
<td>4.11% Upr, -4.45% Lwr</td>
<td>150mg (Upr), -149mg (Lwr)</td>
</tr>
<tr>
<td>3651 - 3990</td>
<td>3800</td>
<td>4.76% Upr, -4.08% Lwr</td>
<td>190mg (Upr), -149mg (Lwr)</td>
</tr>
<tr>
<td>3991 - 4400</td>
<td>4200</td>
<td>4.55% Upr, 5.24% Lwr</td>
<td>200mg (Upr), -209mg (Lwr)</td>
</tr>
<tr>
<td>4401 - 4800</td>
<td>4600</td>
<td>4.17% Upr, -4.52% Lwr</td>
<td>200mg (Upr), -199mg (Lwr)</td>
</tr>
<tr>
<td>4801 - 5250</td>
<td>5000</td>
<td>4.76% Upr, -4.14% Lwr</td>
<td>250mg (Upr), -199mg (Lwr)</td>
</tr>
<tr>
<td>5251 - 5750</td>
<td>5500</td>
<td>4.35% Upr, -4.74% Lwr</td>
<td>250mg (Upr), -249mg (Lwr)</td>
</tr>
<tr>
<td>5751 - 6250</td>
<td>6000</td>
<td>4.00% Upr, -4.33% Lwr</td>
<td>250mg (Upr), -249mg (Lwr)</td>
</tr>
<tr>
<td>6251 - 6750</td>
<td>6500</td>
<td>3.70% Upr, -3.98% Lwr</td>
<td>250mg (Upr), -249mg (Lwr)</td>
</tr>
<tr>
<td>6751 - 7250</td>
<td>7000</td>
<td>3.45% Upr, -3.69% Lwr</td>
<td>250mg (Upr), -249mg (Lwr)</td>
</tr>
<tr>
<td>7251 - 7750</td>
<td>7500</td>
<td>3.23% Upr, -3.43% Lwr</td>
<td>250mg (Upr), -249mg (Lwr)</td>
</tr>
</tbody>
</table>
**CYTARABINE IV INFUSION (Version 1):**
The dose bands used in this table are constructed based on a 100mg/ml concentration of cytarabine
Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume

<table>
<thead>
<tr>
<th>Dose Range (mg)</th>
<th>Banded Dose (mg)</th>
<th>Maximum variation range (%)</th>
<th>Maximum variation range (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>125 - 134</td>
<td>130</td>
<td>2.99% (Upr)*, -4.00% (Lwr)</td>
<td>4mg (Upr), -5mg (Lwr)</td>
</tr>
<tr>
<td>135 - 144</td>
<td>140</td>
<td>2.78% (Upr)*, -3.70% (Lwr)</td>
<td>4mg (Upr), -5mg (Lwr)</td>
</tr>
<tr>
<td>145 - 154</td>
<td>150</td>
<td>2.60% (Upr)*, -3.45% (Lwr)</td>
<td>4mg (Upr), -5mg (Lwr)</td>
</tr>
<tr>
<td>155 - 169</td>
<td>160</td>
<td>5.33% (Upr)*, -3.23% (Lwr)</td>
<td>9mg (Upr), -5mg (Lwr)</td>
</tr>
<tr>
<td>170 - 189</td>
<td>180</td>
<td>4.76% (Upr)*, -5.88% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>190 - 209</td>
<td>200</td>
<td>4.31% (Upr)*, -5.26% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>210 - 229</td>
<td>220</td>
<td>3.93% (Upr)*, -4.76% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>230 - 249</td>
<td>240</td>
<td>3.61% (Upr)*, -4.35% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>250 - 269</td>
<td>260</td>
<td>3.35% (Upr)*, -4.00% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>270 - 289</td>
<td>280</td>
<td>3.11% (Upr)*, -3.70% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>290 - 309</td>
<td>300</td>
<td>2.91% (Upr)*, -3.45% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>310 - 329</td>
<td>320</td>
<td>2.74% (Upr)*, -3.23% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>330 - 349</td>
<td>340</td>
<td>2.58% (Upr)*, -3.03% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>350 - 379</td>
<td>360</td>
<td>5.01% (Upr)*, -2.86% (Lwr)</td>
<td>19mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>380 - 419</td>
<td>400</td>
<td>4.53% (Upr)*, -4.26% (Lwr)</td>
<td>19mg (Upr), -20mg (Lwr)</td>
</tr>
<tr>
<td>420 - 459</td>
<td>440</td>
<td>4.14% (Upr)*, -4.76% (Lwr)</td>
<td>19mg (Upr), -20mg (Lwr)</td>
</tr>
<tr>
<td>460 - 499</td>
<td>480</td>
<td>3.81% (Upr)*, -4.35% (Lwr)</td>
<td>19mg (Upr), -20mg (Lwr)</td>
</tr>
<tr>
<td>500 - 539</td>
<td>520</td>
<td>3.53% (Upr)*, -4.00% (Lwr)</td>
<td>19mg (Upr), -20mg (Lwr)</td>
</tr>
<tr>
<td>540 - 579</td>
<td>560</td>
<td>3.28% (Upr)*, -3.70% (Lwr)</td>
<td>19mg (Upr), -20mg (Lwr)</td>
</tr>
<tr>
<td>580 - 625</td>
<td>600</td>
<td>4.00% (Upr)*, -3.45% (Lwr)</td>
<td>25mg (Upr), -20mg (Lwr)</td>
</tr>
<tr>
<td>626 - 675</td>
<td>650</td>
<td>3.70% (Upr)*, -3.83% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>676 - 725</td>
<td>700</td>
<td>3.45% (Upr)*, -3.55% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>726 - 775</td>
<td>750</td>
<td>3.23% (Upr)*, -3.31% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>776 - 825</td>
<td>800</td>
<td>3.03% (Upr)*, -3.09% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>826 - 875</td>
<td>850</td>
<td>2.86% (Upr)*, -2.91% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>876 - 925</td>
<td>900</td>
<td>2.70% (Upr)*, -2.74% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>926 - 975</td>
<td>950</td>
<td>2.56% (Upr)*, -2.59% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>976 - 1050</td>
<td>1000</td>
<td>4.76% (Upr)*, -2.46% (Lwr)</td>
<td>50mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>CYTARABINE IV INFUSION (Version 1) continued</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1051 - 1150</td>
<td>1100</td>
<td>4.35% (Upr)”, -4.66% (Lwr)</td>
<td>50mg (Upr), -49mg (Lwr)</td>
</tr>
<tr>
<td>1151 - 1250</td>
<td>1200</td>
<td>4.00% (Upr)”, -4.26% (Lwr)</td>
<td>50mg (Upr), -49mg (Lwr)</td>
</tr>
<tr>
<td>1251 - 1350</td>
<td>1300</td>
<td>3.70% (Upr)”, -3.92% (Lwr)</td>
<td>50mg (Upr), -49mg (Lwr)</td>
</tr>
<tr>
<td>1351 - 1470</td>
<td>1400</td>
<td>4.76% (Upr)”, -3.63% (Lwr)</td>
<td>70mg (Upr), -49mg (Lwr)</td>
</tr>
<tr>
<td>1471 - 1600</td>
<td>1540</td>
<td>3.75% (Upr)”, -4.69% (Lwr)</td>
<td>60mg (Upr), -69mg (Lwr)</td>
</tr>
<tr>
<td>1601 - 1740</td>
<td>1680</td>
<td>3.45% (Upr)”, -4.93% (Lwr)</td>
<td>60mg (Upr), -79mg (Lwr)</td>
</tr>
<tr>
<td>1741 - 1900</td>
<td>1820</td>
<td>4.21% (Upr)”, -4.54% (Lwr)</td>
<td>80mg (Upr), -79mg (Lwr)</td>
</tr>
<tr>
<td>1901 - 2100</td>
<td>2000</td>
<td>4.76% (Upr)”, -5.21% (Lwr)</td>
<td>100mg (Upr), -99mg (Lwr)</td>
</tr>
<tr>
<td>2101 - 2300</td>
<td>2200</td>
<td>4.35% (Upr)”, -4.71% (Lwr)</td>
<td>100mg (Upr), -99mg (Lwr)</td>
</tr>
<tr>
<td>2301 - 2520</td>
<td>2400</td>
<td>4.76% (Upr)”, -4.30% (Lwr)</td>
<td>120mg (Upr), -99mg (Lwr)</td>
</tr>
<tr>
<td>2521 - 2760</td>
<td>2640</td>
<td>4.35% (Upr)”, -4.72% (Lwr)</td>
<td>120mg (Upr), -119mg (Lwr)</td>
</tr>
<tr>
<td>2761 - 3050</td>
<td>2900</td>
<td>4.92% (Upr)”, 5.03% (Lwr)</td>
<td>150mg (Upr), -139mg (Lwr)</td>
</tr>
<tr>
<td>3051 - 3350</td>
<td>3200</td>
<td>4.48% (Upr)”, -4.88% (Lwr)</td>
<td>150mg (Upr), -149mg (Lwr)</td>
</tr>
<tr>
<td>3351 - 3650</td>
<td>3500</td>
<td>4.11% (Upr)”, -4.45% (Lwr)</td>
<td>150mg (Upr), -149mg (Lwr)</td>
</tr>
<tr>
<td>3651 - 3990</td>
<td>3800</td>
<td>4.76% (Upr)”, -4.08% (Lwr)</td>
<td>190mg (Upr), -149mg (Lwr)</td>
</tr>
<tr>
<td>3991 - 4400</td>
<td>4200</td>
<td>4.55% (Upr)”, 5.24% (Lwr)</td>
<td>200mg (Upr), -209mg (Lwr)</td>
</tr>
<tr>
<td>4401 - 4800</td>
<td>4600</td>
<td>4.17% (Upr)”, -4.52% (Lwr)</td>
<td>200mg (Upr), -199mg (Lwr)</td>
</tr>
<tr>
<td>4801 - 5250</td>
<td>5000</td>
<td>4.76% (Upr)”, -4.14% (Lwr)</td>
<td>250mg (Upr), -199mg (Lwr)</td>
</tr>
<tr>
<td>5251 - 5750</td>
<td>5500</td>
<td>4.35% (Upr)”, -4.74% (Lwr)</td>
<td>250mg (Upr), -249mg (Lwr)</td>
</tr>
<tr>
<td>5751 - 6250</td>
<td>6000</td>
<td>4.00% (Upr)”, -4.33% (Lwr)</td>
<td>250mg (Upr), -249mg (Lwr)</td>
</tr>
<tr>
<td>6251 - 6750</td>
<td>6500</td>
<td>3.70% (Upr)”, -3.98% (Lwr)</td>
<td>250mg (Upr), -249mg (Lwr)</td>
</tr>
<tr>
<td>6751 - 7250</td>
<td>7000</td>
<td>3.45% (Upr)”, -3.69% (Lwr)</td>
<td>250mg (Upr), -249mg (Lwr)</td>
</tr>
<tr>
<td>7251 - 7750</td>
<td>7500</td>
<td>3.23% (Upr)”, -3.43% (Lwr)</td>
<td>250mg (Upr), -249mg (Lwr)</td>
</tr>
<tr>
<td>7751 - 8250</td>
<td>8000</td>
<td>3.03% (Upr)”, -3.21% (Lwr)</td>
<td>250mg (Upr), -249mg (Lwr)</td>
</tr>
<tr>
<td>8251 - 8750</td>
<td>8500</td>
<td>2.86% (Upr)”, -3.02% (Lwr)</td>
<td>250mg (Upr), -249mg (Lwr)</td>
</tr>
</tbody>
</table>
DOCETAXEL IV INFUSION (Version 2)

The dose bands used in this table are constructed based on a 20mg/ml concentration of docetaxel.
Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

<table>
<thead>
<tr>
<th>Dose Range (mg)</th>
<th>Banded Dose (mg)</th>
<th>Maximum variation range (%)</th>
<th>Maximum variation range (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>31 - 33</td>
<td>32</td>
<td>3.03% (Upr)*, -3.23% (Lwr)</td>
<td>1mg (Upr), -1mg (Lwr)</td>
</tr>
<tr>
<td>34 - 37</td>
<td>36</td>
<td>2.70% (Upr)*, -5.88% (Lwr)</td>
<td>1mg (Upr), -2mg (Lwr)</td>
</tr>
<tr>
<td>38 - 42</td>
<td>40</td>
<td>4.76% (Upr)*, -5.26% (Lwr)</td>
<td>2mg (Upr), -2mg (Lwr)</td>
</tr>
<tr>
<td>43 - 46</td>
<td>44</td>
<td>4.35% (Upr)*, -2.33% (Lwr)</td>
<td>2mg (Upr), -1mg (Lwr)</td>
</tr>
<tr>
<td>47 - 50</td>
<td>48</td>
<td>4.00% (Upr)*, -2.13% (Lwr)</td>
<td>2mg (Upr), -1mg (Lwr)</td>
</tr>
<tr>
<td>51 - 54</td>
<td>52</td>
<td>3.70% (Upr)*, -1.96% (Lwr)</td>
<td>2mg (Upr), -1mg (Lwr)</td>
</tr>
<tr>
<td>55 - 58</td>
<td>56</td>
<td>3.45% (Upr)*, -1.82% (Lwr)</td>
<td>2mg (Upr), -1mg (Lwr)</td>
</tr>
<tr>
<td>59 - 62</td>
<td>60</td>
<td>3.23% (Upr)*, -1.69% (Lwr)</td>
<td>2mg (Upr), -1mg (Lwr)</td>
</tr>
<tr>
<td>63 - 66</td>
<td>64</td>
<td>3.03% (Upr)*, -1.59% (Lwr)</td>
<td>2mg (Upr), -1mg (Lwr)</td>
</tr>
<tr>
<td>67 - 70</td>
<td>68</td>
<td>2.86% (Upr)*, -1.49% (Lwr)</td>
<td>2mg (Upr), -1mg (Lwr)</td>
</tr>
<tr>
<td>71 - 75</td>
<td>72</td>
<td>4.00% (Upr)*, -1.41% (Lwr)</td>
<td>3mg (Upr), -1mg (Lwr)</td>
</tr>
<tr>
<td>76 - 84</td>
<td>80</td>
<td>4.76% (Upr)*, -5.26% (Lwr)</td>
<td>4mg (Upr), -4mg (Lwr)</td>
</tr>
<tr>
<td>85 - 92</td>
<td>88</td>
<td>4.35% (Upr)*, -3.53% (Lwr)</td>
<td>4mg (Upr), -3mg (Lwr)</td>
</tr>
<tr>
<td>93 - 100</td>
<td>96</td>
<td>4.00% (Upr)*, -3.23% (Lwr)</td>
<td>4mg (Upr), -3mg (Lwr)</td>
</tr>
<tr>
<td>101 - 108</td>
<td>104</td>
<td>3.70% (Upr)*, -2.97% (Lwr)</td>
<td>4mg (Upr), -3mg (Lwr)</td>
</tr>
<tr>
<td>109 - 116</td>
<td>112</td>
<td>3.45% (Upr)*, -2.75% (Lwr)</td>
<td>4mg (Upr), -3mg (Lwr)</td>
</tr>
<tr>
<td>117 - 126</td>
<td>120</td>
<td>4.76% (Upr)*, -2.56% (Lwr)</td>
<td>6mg (Upr), -3mg (Lwr)</td>
</tr>
<tr>
<td>127 - 138</td>
<td>132</td>
<td>4.35% (Upr)*, -3.94% (Lwr)</td>
<td>6mg (Upr), -5mg (Lwr)</td>
</tr>
<tr>
<td>139 - 150</td>
<td>144</td>
<td>4.00% (Upr)*, -3.60% (Lwr)</td>
<td>6mg (Upr), -5mg (Lwr)</td>
</tr>
<tr>
<td>151 - 162</td>
<td>156</td>
<td>3.70% (Upr)*, -3.31% (Lwr)</td>
<td>6mg (Upr), -5mg (Lwr)</td>
</tr>
<tr>
<td>163 - 174</td>
<td>168</td>
<td>3.45% (Upr)*, -3.07% (Lwr)</td>
<td>6mg (Upr), -5mg (Lwr)</td>
</tr>
<tr>
<td>175 - 189</td>
<td>180</td>
<td>4.76% (Upr)*, -2.86% (Lwr)</td>
<td>9mg (Upr), -5mg (Lwr)</td>
</tr>
<tr>
<td>190 - 209</td>
<td>200</td>
<td>4.31% (Upr)*, -5.26% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>210 - 229</td>
<td>220</td>
<td>3.93% (Upr)*, -4.76% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>230 - 249</td>
<td>240</td>
<td>3.61% (Upr)*, -4.35% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
</tbody>
</table>
ETOPOSIDE IV INFUSION (Version 1):
The dose bands used in this table are constructed based on a 20mg/ml concentration of etoposide.
Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

<table>
<thead>
<tr>
<th>Dose Range (mg)</th>
<th>Banded Dose (mg)</th>
<th>Maximum variation range (%)</th>
<th>Maximum variation range (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>58 - 62</td>
<td>60</td>
<td>3.23% (Upr)**, -3.45% (Lwr)</td>
<td>2mg (Upr), -2mg (Lwr)</td>
</tr>
<tr>
<td>63 - 66</td>
<td>64</td>
<td>3.03% (Upr)**, -1.59% (Lwr)</td>
<td>2mg (Upr), -1mg (Lwr)</td>
</tr>
<tr>
<td>67 - 70</td>
<td>68</td>
<td>2.86% (Upr)**, -1.49% (Lwr)</td>
<td>2mg (Upr), -1mg (Lwr)</td>
</tr>
<tr>
<td>71 - 76</td>
<td>72</td>
<td>5.26% (Upr)**, -1.41% (Lwr)</td>
<td>4mg (Upr), -1mg (Lwr)</td>
</tr>
<tr>
<td>77 - 84</td>
<td>80</td>
<td>4.76% (Upr)**, -3.90% (Lwr)</td>
<td>4mg (Upr), -3mg (Lwr)</td>
</tr>
<tr>
<td>85 - 92</td>
<td>88</td>
<td>4.35% (Upr)**, -3.53% (Lwr)</td>
<td>4mg (Upr), -3mg (Lwr)</td>
</tr>
<tr>
<td>93 - 100</td>
<td>96</td>
<td>4.00% (Upr)**, -3.23% (Lwr)</td>
<td>4mg (Upr), -3mg (Lwr)</td>
</tr>
<tr>
<td>101 - 108</td>
<td>104</td>
<td>3.70% (Upr)**, -2.97% (Lwr)</td>
<td>4mg (Upr), -3mg (Lwr)</td>
</tr>
<tr>
<td>109 - 116</td>
<td>112</td>
<td>3.45% (Upr)**, -2.75% (Lwr)</td>
<td>4mg (Upr), -3mg (Lwr)</td>
</tr>
<tr>
<td>117 - 126</td>
<td>120</td>
<td>4.76% (Upr)**, -2.56% (Lwr)</td>
<td>6mg (Upr), -3mg (Lwr)</td>
</tr>
<tr>
<td>127 - 138</td>
<td>132</td>
<td>4.35% (Upr)**, -3.94% (Lwr)</td>
<td>6mg (Upr), -5mg (Lwr)</td>
</tr>
<tr>
<td>139 - 150</td>
<td>144</td>
<td>4.00% (Upr)**, -3.60% (Lwr)</td>
<td>6mg (Upr), -5mg (Lwr)</td>
</tr>
<tr>
<td>151 - 162</td>
<td>156</td>
<td>3.70% (Upr)**, -3.31% (Lwr)</td>
<td>6mg (Upr), -5mg (Lwr)</td>
</tr>
<tr>
<td>163 - 174</td>
<td>168</td>
<td>3.45% (Upr)**, -3.07% (Lwr)</td>
<td>6mg (Upr), -5mg (Lwr)</td>
</tr>
<tr>
<td>175 - 189</td>
<td>180</td>
<td>4.76% (Upr)**, -2.86% (Lwr)</td>
<td>9mg (Upr), -5mg (Lwr)</td>
</tr>
<tr>
<td>190 - 209</td>
<td>200</td>
<td>4.31% (Upr)**, -5.26% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>210 - 229</td>
<td>220</td>
<td>3.93% (Upr)**, -4.76% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>230 - 249</td>
<td>240</td>
<td>3.61% (Upr)**, -4.35% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>250 - 269</td>
<td>260</td>
<td>3.35% (Upr)**, -4.00% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>270 - 289</td>
<td>280</td>
<td>3.11% (Upr)**, -3.70% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>290 - 309</td>
<td>300</td>
<td>2.91% (Upr)**, -3.45% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>310 - 329</td>
<td>320</td>
<td>2.74% (Upr)**, -3.23% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>330 - 349</td>
<td>340</td>
<td>2.58% (Upr)**, -3.03% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>350 - 379</td>
<td>360</td>
<td>5.01% (Upr)**, -2.86% (Lwr)</td>
<td>19mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>380 - 420</td>
<td>400</td>
<td>4.76% (Upr)**, 5.26% (Lwr)</td>
<td>20mg (Upr), -20mg (Lwr)</td>
</tr>
</tbody>
</table>
5-FLUOROURACIL IV INFUSION (Version 1):
The dose bands used in this table are constructed based on a 25mg/ml concentration of 5-fluorouracil.
Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

<table>
<thead>
<tr>
<th>Dose Range (mg)</th>
<th>Banded Dose (mg)</th>
<th>Maximum variation range (%)</th>
<th>Maximum variation range (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>238 - 262</td>
<td>250</td>
<td>4.58% (Upr)* , 5.04% (Lwr)</td>
<td>12mg (Upr), -12mg (Lwr)</td>
</tr>
<tr>
<td>263 - 287</td>
<td>275</td>
<td>4.18% (Upr)* , -4.56% (Lwr)</td>
<td>12mg (Upr), -12mg (Lwr)</td>
</tr>
<tr>
<td>288 - 312</td>
<td>300</td>
<td>3.85% (Upr)* , -4.17% (Lwr)</td>
<td>12mg (Upr), -12mg (Lwr)</td>
</tr>
<tr>
<td>313 - 337</td>
<td>325</td>
<td>3.56% (Upr)* , -3.83% (Lwr)</td>
<td>12mg (Upr), -12mg (Lwr)</td>
</tr>
<tr>
<td>338 - 362</td>
<td>350</td>
<td>3.31% (Upr)* , -3.55% (Lwr)</td>
<td>12mg (Upr), -12mg (Lwr)</td>
</tr>
<tr>
<td>363 - 387</td>
<td>375</td>
<td>3.10% (Upr)* , -3.31% (Lwr)</td>
<td>12mg (Upr), -12mg (Lwr)</td>
</tr>
<tr>
<td>388 - 424</td>
<td>400</td>
<td>3.66% (Upr)* , -3.09% (Lwr)</td>
<td>24mg (Upr), -12mg (Lwr)</td>
</tr>
<tr>
<td>425 - 474</td>
<td>450</td>
<td>5.06% (Upr)* , -5.88% (Lwr)</td>
<td>24mg (Upr), -25mg (Lwr)</td>
</tr>
<tr>
<td>475 - 525</td>
<td>500</td>
<td>4.76% (Upr)* , -5.26% (Lwr)</td>
<td>25mg (Upr), -25mg (Lwr)</td>
</tr>
<tr>
<td>526 - 575</td>
<td>550</td>
<td>4.35% (Upr)* , -4.56% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>576 - 625</td>
<td>600</td>
<td>4.00% (Upr)* , -4.17% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>626 - 675</td>
<td>650</td>
<td>3.70% (Upr)* , -3.83% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>676 - 725</td>
<td>700</td>
<td>3.45% (Upr)* , -3.55% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>726 - 775</td>
<td>750</td>
<td>3.23% (Upr)* , -3.31% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>776 - 825</td>
<td>800</td>
<td>3.03% (Upr)* , -3.09% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>826 - 875</td>
<td>850</td>
<td>2.86% (Upr)* , -2.91% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>876 - 925</td>
<td>900</td>
<td>2.70% (Upr)* , -2.74% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>926 - 975</td>
<td>950</td>
<td>2.56% (Upr)* , -2.59% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>976 - 1050</td>
<td>1000</td>
<td>4.76% (Upr)* , -2.46% (Lwr)</td>
<td>50mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>1051 - 1150</td>
<td>1100</td>
<td>4.35% (Upr)* , -4.66% (Lwr)</td>
<td>50mg (Upr), -49mg (Lwr)</td>
</tr>
<tr>
<td>1151 - 1250</td>
<td>1200</td>
<td>4.00% (Upr)* , -4.26% (Lwr)</td>
<td>50mg (Upr), -49mg (Lwr)</td>
</tr>
<tr>
<td>1251 - 1350</td>
<td>1300</td>
<td>3.70% (Upr)* , -3.92% (Lwr)</td>
<td>50mg (Upr), -49mg (Lwr)</td>
</tr>
<tr>
<td>1351 - 1450</td>
<td>1400</td>
<td>3.45% (Upr)* , -3.63% (Lwr)</td>
<td>50mg (Upr), -49mg (Lwr)</td>
</tr>
<tr>
<td>1451 - 1550</td>
<td>1500</td>
<td>3.23% (Upr)* , -3.38% (Lwr)</td>
<td>50mg (Upr), -49mg (Lwr)</td>
</tr>
<tr>
<td>1551 - 1650</td>
<td>1600</td>
<td>3.03% (Upr)* , -3.16% (Lwr)</td>
<td>50mg (Upr), -49mg (Lwr)</td>
</tr>
<tr>
<td>1651 - 1775</td>
<td>1700</td>
<td>4.23% (Upr)* , -2.97% (Lwr)</td>
<td>75mg (Upr), -49mg (Lwr)</td>
</tr>
<tr>
<td>1776 - 1925</td>
<td>1850</td>
<td>3.90% (Upr)* , -4.17% (Lwr)</td>
<td>75mg (Upr), -74mg (Lwr)</td>
</tr>
<tr>
<td>1926 - 2100</td>
<td>2000</td>
<td>4.76% (Upr)* , -3.84% (Lwr)</td>
<td>100mg (Upr), -74mg (Lwr)</td>
</tr>
</tbody>
</table>

NCCP Dose Banding Tables Published: July 2017
Review: July 2019
Version: 2

This information is valid only on the day of printing, for any updates please check [www.hse.ie/nccpdosebanding](http://www.hse.ie/nccpdosebanding)
## 5-FLUOROURACIL IV Infusion (Version 1) continued

<table>
<thead>
<tr>
<th>Range</th>
<th>Volume</th>
<th>Upper</th>
<th>Lower</th>
</tr>
</thead>
<tbody>
<tr>
<td>2101 - 2300</td>
<td>2200</td>
<td>4.35% (Upr)* , -4.71% (Lwr)</td>
<td>100mg (Upr), -99mg (Lwr)</td>
</tr>
<tr>
<td>2301 - 2500</td>
<td>2400</td>
<td>4.00% (Upr)* , -4.30% (Lwr)</td>
<td>100mg (Upr), -99mg (Lwr)</td>
</tr>
<tr>
<td>2501 - 2700</td>
<td>2600</td>
<td>3.70% (Upr)* , -3.96% (Lwr)</td>
<td>100mg (Upr), -99mg (Lwr)</td>
</tr>
<tr>
<td>2701 - 2900</td>
<td>2800</td>
<td>3.45% (Upr)* , -3.67% (Lwr)</td>
<td>100mg (Upr), -99mg (Lwr)</td>
</tr>
<tr>
<td>2901 - 3150</td>
<td>3000</td>
<td>4.76% (Upr)* , -3.41% (Lwr)</td>
<td>150mg (Upr), -99mg (Lwr)</td>
</tr>
<tr>
<td>3151 - 3450</td>
<td>3300</td>
<td>4.35% (Upr)* , -4.73% (Lwr)</td>
<td>150mg (Upr), -149mg (Lwr)</td>
</tr>
<tr>
<td>3451 - 3750</td>
<td>3600</td>
<td>4.00% (Upr)* , -4.32% (Lwr)</td>
<td>150mg (Upr), -149mg (Lwr)</td>
</tr>
<tr>
<td>3751 - 4050</td>
<td>3900</td>
<td>3.70% (Upr)* , -3.97% (Lwr)</td>
<td>150mg (Upr), -149mg (Lwr)</td>
</tr>
<tr>
<td>4051 - 4400</td>
<td>4200</td>
<td>4.55% (Upr)* , -3.68% (Lwr)</td>
<td>200mg (Upr), -149mg (Lwr)</td>
</tr>
<tr>
<td>4401 - 4800</td>
<td>4600</td>
<td>4.17% (Upr)* , -4.52% (Lwr)</td>
<td>200mg (Upr), -199mg (Lwr)</td>
</tr>
<tr>
<td>4801 - 5200</td>
<td>5000</td>
<td>3.85% (Upr)* , -4.14% (Lwr)</td>
<td>200mg (Upr), -199mg (Lwr)</td>
</tr>
<tr>
<td>5201 - 5600</td>
<td>5400</td>
<td>3.57% (Upr)* , -3.83% (Lwr)</td>
<td>200mg (Upr), -199mg (Lwr)</td>
</tr>
<tr>
<td>5601 - 6100</td>
<td>5800</td>
<td>4.92% (Upr)* , -3.55% (Lwr)</td>
<td>300mg (Upr), -199mg (Lwr)</td>
</tr>
<tr>
<td>6101 - 6700</td>
<td>6400</td>
<td>4.48% (Upr)* , -4.90% (Lwr)</td>
<td>300mg (Upr), -299mg (Lwr)</td>
</tr>
<tr>
<td>6701 - 7300</td>
<td>7000</td>
<td>4.11% (Upr)* , -4.46% (Lwr)</td>
<td>300mg (Upr), -299mg (Lwr)</td>
</tr>
<tr>
<td>7301 - 8000</td>
<td>7600</td>
<td>5.00% (Upr)* , -4.10% (Lwr)</td>
<td>400mg (Upr), -299mg (Lwr)</td>
</tr>
<tr>
<td>8001 - 8800</td>
<td>8400</td>
<td>4.55% (Upr)* , -4.99% (Lwr)</td>
<td>400mg (Upr), -399mg (Lwr)</td>
</tr>
<tr>
<td>8801 - 9600</td>
<td>9200</td>
<td>4.17% (Upr)* , -4.53% (Lwr)</td>
<td>400mg (Upr), -399mg (Lwr)</td>
</tr>
</tbody>
</table>

---

This information is valid only on the day of printing. For any updates please check [www.hse.ie/nccpdosebanding](http://www.hse.ie/nccpdosebanding)
5-FLUOROURACIL INFUSORS (Version 2);
The dose bands used in this table are constructed based on a 50mg/ml concentration of 5-fluorouracil

<table>
<thead>
<tr>
<th>Dose Range (mg)</th>
<th>Banded Dose (mg)</th>
<th>Maximum variation range (%)</th>
<th>Maximum variation range (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2875 - 3150</td>
<td>3000</td>
<td>4.76% (Upr)*, -4.35% (Lwr)</td>
<td>150mg (Upr), -125mg (Lwr)</td>
</tr>
<tr>
<td>3151 - 3450</td>
<td>3300</td>
<td>4.35% (Upr)*, -4.73% (Lwr)</td>
<td>150mg (Upr), -149mg (Lwr)</td>
</tr>
<tr>
<td>3451 - 3750</td>
<td>3600</td>
<td>4.00% (Upr)*, -4.32% (Lwr)</td>
<td>150mg (Upr), -149mg (Lwr)</td>
</tr>
<tr>
<td>3751 - 4050</td>
<td>3900</td>
<td>3.70% (Upr)*, -3.97% (Lwr)</td>
<td>150mg (Upr), -149mg (Lwr)</td>
</tr>
<tr>
<td>4051 - 4400</td>
<td>4200</td>
<td>4.55% (Upr)*, -3.68% (Lwr)</td>
<td>200mg (Upr), -149mg (Lwr)</td>
</tr>
<tr>
<td>4401 - 4800</td>
<td>4600</td>
<td>4.17% (Upr)*, -4.52% (Lwr)</td>
<td>200mg (Upr), -199mg (Lwr)</td>
</tr>
<tr>
<td>4801 - 5200</td>
<td>5000</td>
<td>3.85% (Upr)*, -4.14% (Lwr)</td>
<td>200mg (Upr), -199mg (Lwr)</td>
</tr>
<tr>
<td>5201 - 5600</td>
<td>5400</td>
<td>3.57% (Upr)*, -3.83% (Lwr)</td>
<td>200mg (Upr), -199mg (Lwr)</td>
</tr>
<tr>
<td>5601 - 6100</td>
<td>5800</td>
<td>4.92% (Upr)*, -3.55% (Lwr)</td>
<td>200mg (Upr), -199mg (Lwr)</td>
</tr>
<tr>
<td>6101 - 6700</td>
<td>6400</td>
<td>4.48% (Upr)*, -4.90% (Lwr)</td>
<td>200mg (Upr), -299mg (Lwr)</td>
</tr>
<tr>
<td>6701 - 7300</td>
<td>7000</td>
<td>4.11% (Upr)*, -4.46% (Lwr)</td>
<td>200mg (Upr), -299mg (Lwr)</td>
</tr>
<tr>
<td>7301 - 8000</td>
<td>7600</td>
<td>5.00% (Upr)*, -4.10% (Lwr)</td>
<td>200mg (Upr), -299mg (Lwr)</td>
</tr>
<tr>
<td>8001 - 8800</td>
<td>8400</td>
<td>4.55% (Upr)*, -4.99% (Lwr)</td>
<td>200mg (Upr), -399mg (Lwr)</td>
</tr>
<tr>
<td>8801 - 9600</td>
<td>9200</td>
<td>4.17% (Upr)*, -4.53% (Lwr)</td>
<td>200mg (Upr), -399mg (Lwr)</td>
</tr>
</tbody>
</table>
**40mg/ml GEMCITABINE IV INFUSION (Version 2);**

The dose bands used in this table are constructed based on a **40mg/ml** concentration of gemcitabine

This table is the nationally recommended dose band table for gemcitabine. An alternate table is supplied for certain sites who use gemcitabine 38mg/ml and wish to dose band locally using this concentration.

*Please note that there are two tables for gemcitabine with different concentrations. Please ensure to use the dose bands applicable to the concentration used in your local site. This should be defined in your dose banding procedures.*

<table>
<thead>
<tr>
<th>Dose Range (mg)</th>
<th>Banded Dose (mg)</th>
<th>Maximum variation range (%)</th>
<th>Maximum variation range (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>950 - 1040</td>
<td>1000</td>
<td>3.85% (Upr)*, 5.26% (Lwr)</td>
<td>40mg (Upr), -50mg (Lwr)</td>
</tr>
<tr>
<td>1041 - 1120</td>
<td>1080</td>
<td>3.57% (Upr)*, -3.75% (Lwr)</td>
<td>40mg (Upr), -39mg (Lwr)</td>
</tr>
<tr>
<td>1121 - 1200</td>
<td>1160</td>
<td>3.33% (Upr)*, -3.48% (Lwr)</td>
<td>40mg (Upr), -39mg (Lwr)</td>
</tr>
<tr>
<td>1201 - 1300</td>
<td>1240</td>
<td>4.62% (Upr)*, -3.25% (Lwr)</td>
<td>60mg (Upr), -39mg (Lwr)</td>
</tr>
<tr>
<td>1301 - 1420</td>
<td>1360</td>
<td>4.23% (Upr)*, -4.53% (Lwr)</td>
<td>60mg (Upr), -59mg (Lwr)</td>
</tr>
<tr>
<td>1421 - 1540</td>
<td>1480</td>
<td>3.90% (Upr)*, -4.15% (Lwr)</td>
<td>60mg (Upr), -59mg (Lwr)</td>
</tr>
<tr>
<td>1541 - 1660</td>
<td>1600</td>
<td>3.61% (Upr)*, -3.83% (Lwr)</td>
<td>60mg (Upr), -59mg (Lwr)</td>
</tr>
<tr>
<td>1661 - 1780</td>
<td>1720</td>
<td>3.37% (Upr)*, -3.55% (Lwr)</td>
<td>60mg (Upr), -59mg (Lwr)</td>
</tr>
<tr>
<td>1781 - 1920</td>
<td>1840</td>
<td>4.17% (Upr)*, -3.31% (Lwr)</td>
<td>80mg (Upr), -59mg (Lwr)</td>
</tr>
<tr>
<td>1921 - 2100</td>
<td>2000</td>
<td>4.76% (Upr)*, -4.11% (Lwr)</td>
<td>100mg (Upr), -79mg (Lwr)</td>
</tr>
<tr>
<td>2101 - 2300</td>
<td>2200</td>
<td>4.35% (Upr)*, -4.71% (Lwr)</td>
<td>100mg (Upr), -89mg (Lwr)</td>
</tr>
<tr>
<td>2301 - 2500</td>
<td>2400</td>
<td>4.00% (Upr)*, -4.30% (Lwr)</td>
<td>100mg (Upr), -99mg (Lwr)</td>
</tr>
</tbody>
</table>

This information is valid only on the day of printing, for any updates please check [www.hse.ie/nccpdosebanding](http://www.hse.ie/nccpdosebanding)
**38mg/ml GEMCITABINE IV INFUSION (Version 2);**

The dose bands used in this table are constructed based on a **38mg/ml** concentration of gemcitabine

This table is **NOT the nationally recommended** dose band table for gemcitabine. The nationally recommended dose band table is supplied for gemcitabine 40mg/ml. This table is supplied as an alternative for those who wish to use gemcitabine 38mg/ml and dose band locally using this concentration.

*Please note that there are two tables for gemcitabine with different concentrations. Please ensure to use the dose bands applicable to the concentration used in your local site. This should be defined in your dose banding procedures.*

<table>
<thead>
<tr>
<th>Dose Range (mg)</th>
<th>Banded Dose (mg)</th>
<th>Maximum variation range (%)</th>
<th>Maximum variation range (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>975 - 1064</td>
<td>1026</td>
<td>3.57% (Upr)*, 5.23% (Lwr)</td>
<td>38mg (Upr), -51mg (Lwr)</td>
</tr>
<tr>
<td>1065 - 1139</td>
<td>1102</td>
<td>3.25% (Upr)*, -3.47% (Lwr)</td>
<td>37mg (Upr), -37mg (Lwr)</td>
</tr>
<tr>
<td>1140 - 1216</td>
<td>1178</td>
<td>3.13% (Upr)*, -3.33% (Lwr)</td>
<td>38mg (Upr), -38mg (Lwr)</td>
</tr>
<tr>
<td>1217 - 1292</td>
<td>1254</td>
<td>2.94% (Upr)*, -3.04% (Lwr)</td>
<td>38mg (Upr), -38mg (Lwr)</td>
</tr>
<tr>
<td>1293 - 1368</td>
<td>1330</td>
<td>2.78% (Upr)*, -2.86% (Lwr)</td>
<td>38mg (Upr), -37mg (Lwr)</td>
</tr>
<tr>
<td>1369 - 1520</td>
<td>1444</td>
<td>5.00% (Upr)*, 5.48% (Lwr)</td>
<td>76mg (Upr), -75mg (Lwr)</td>
</tr>
<tr>
<td>1521 - 1672</td>
<td>1596</td>
<td>4.55% (Upr)*, -4.93% (Lwr)</td>
<td>76mg (Upr), -75mg (Lwr)</td>
</tr>
<tr>
<td>1673 - 1824</td>
<td>1748</td>
<td>4.17% (Upr)*, -4.48% (Lwr)</td>
<td>76mg (Upr), -75mg (Lwr)</td>
</tr>
<tr>
<td>1825 - 1995</td>
<td>1900</td>
<td>4.76% (Upr)*, -4.11% (Lwr)</td>
<td>95mg (Upr), -75mg (Lwr)</td>
</tr>
<tr>
<td>1996 - 2166</td>
<td>2090</td>
<td>3.51% (Upr)*, -4.71% (Lwr)</td>
<td>76mg (Upr), -94mg (Lwr)</td>
</tr>
<tr>
<td>2167 - 2356</td>
<td>2280</td>
<td>3.23% (Upr)*, 5.21% (Lwr)</td>
<td>76mg (Upr), -113mg (Lwr)</td>
</tr>
</tbody>
</table>
IRINOTECAN IV INFUSION (Version 2):
The dose bands used in this table are constructed based on a 20mg/ml concentration of irinotecan
Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume

<table>
<thead>
<tr>
<th>Dose Range (mg)</th>
<th>Banded Dose (mg)</th>
<th>Maximum variation range (%)</th>
<th>Maximum variation range (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>190 - 209</td>
<td>200</td>
<td>4.31% (Upr)*, -5.26% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>210 - 229</td>
<td>220</td>
<td>3.93% (Upr)*, -4.76% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>230 - 249</td>
<td>240</td>
<td>3.61% (Upr)*, -4.35% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>250 - 269</td>
<td>260</td>
<td>3.35% (Upr)*, -4.00% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>270 - 289</td>
<td>280</td>
<td>3.11% (Upr)*, -3.70% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>290 - 309</td>
<td>300</td>
<td>2.91% (Upr)*, -3.45% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>310 - 329</td>
<td>320</td>
<td>2.74% (Upr)*, -3.23% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>330 - 349</td>
<td>340</td>
<td>2.58% (Upr)*, -3.03% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>350 - 379</td>
<td>360</td>
<td>2.41% (Upr)*, -2.86% (Lwr)</td>
<td>19mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>380 - 419</td>
<td>400</td>
<td>4.53% (Upr)*, -5.26% (Lwr)</td>
<td>19mg (Upr), -20mg (Lwr)</td>
</tr>
<tr>
<td>420 - 459</td>
<td>440</td>
<td>4.14% (Upr)*, -4.76% (Lwr)</td>
<td>19mg (Upr), -20mg (Lwr)</td>
</tr>
<tr>
<td>460 - 499</td>
<td>480</td>
<td>3.81% (Upr)*, -4.35% (Lwr)</td>
<td>19mg (Upr), -20mg (Lwr)</td>
</tr>
<tr>
<td>500 - 539</td>
<td>520</td>
<td>3.53% (Upr)*, -4.00% (Lwr)</td>
<td>19mg (Upr), -20mg (Lwr)</td>
</tr>
<tr>
<td>540 - 579</td>
<td>560</td>
<td>3.28% (Upr)*, -3.70% (Lwr)</td>
<td>19mg (Upr), -20mg (Lwr)</td>
</tr>
<tr>
<td>580 - 619</td>
<td>600</td>
<td>3.07% (Upr)*, -3.45% (Lwr)</td>
<td>19mg (Upr), -20mg (Lwr)</td>
</tr>
<tr>
<td>620 - 659</td>
<td>640</td>
<td>2.88% (Upr)*, -3.23% (Lwr)</td>
<td>19mg (Upr), -20mg (Lwr)</td>
</tr>
<tr>
<td>660 - 709</td>
<td>680</td>
<td>4.09% (Upr)*, -3.03% (Lwr)</td>
<td>29mg (Upr), -20mg (Lwr)</td>
</tr>
<tr>
<td>710 - 769</td>
<td>740</td>
<td>3.77% (Upr)*, -4.23% (Lwr)</td>
<td>29mg (Upr), -30mg (Lwr)</td>
</tr>
<tr>
<td>770 - 830</td>
<td>800</td>
<td>3.61% (Upr)*, -3.90% (Lwr)</td>
<td>30mg (Upr), -30mg (Lwr)</td>
</tr>
</tbody>
</table>
**METHOTREXATE IV INFUSION (Version 1):**
The dose bands used in this table are constructed based on a 100mg/ml concentration of methotrexate
Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume

<table>
<thead>
<tr>
<th>Dose Range (mg)</th>
<th>Banded Dose (mg)</th>
<th>Maximum variation range (%)</th>
<th>Maximum variation range (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>95 - 104</td>
<td>100</td>
<td>3.85% (Upr), -5.26% (Lwr)</td>
<td>4mg (Upr), -5mg (Lwr)</td>
</tr>
<tr>
<td>105 - 114</td>
<td>110</td>
<td>3.51% (Upr), -4.76% (Lwr)</td>
<td>4mg (Upr), -5mg (Lwr)</td>
</tr>
<tr>
<td>115 - 124</td>
<td>120</td>
<td>3.23% (Upr), -4.35% (Lwr)</td>
<td>4mg (Upr), -5mg (Lwr)</td>
</tr>
<tr>
<td>125 - 134</td>
<td>130</td>
<td>2.99% (Upr), -4.00% (Lwr)</td>
<td>4mg (Upr), -5mg (Lwr)</td>
</tr>
<tr>
<td>135 - 144</td>
<td>140</td>
<td>2.78% (Upr), -3.70% (Lwr)</td>
<td>4mg (Upr), -5mg (Lwr)</td>
</tr>
<tr>
<td>145 - 154</td>
<td>150</td>
<td>2.60% (Upr), -3.45% (Lwr)</td>
<td>4mg (Upr), -5mg (Lwr)</td>
</tr>
<tr>
<td>155 - 169</td>
<td>160</td>
<td>2.33% (Upr), -3.23% (Lwr)</td>
<td>9mg (Upr), -5mg (Lwr)</td>
</tr>
<tr>
<td>170 - 189</td>
<td>180</td>
<td>4.76% (Upr), -5.88% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>190 - 209</td>
<td>200</td>
<td>4.31% (Upr), -5.26% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>210 - 229</td>
<td>220</td>
<td>3.93% (Upr), -4.76% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>230 - 249</td>
<td>240</td>
<td>3.61% (Upr), -4.35% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>250 - 269</td>
<td>260</td>
<td>3.35% (Upr), -4.00% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>270 - 289</td>
<td>280</td>
<td>3.11% (Upr), -3.70% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>290 - 309</td>
<td>300</td>
<td>2.91% (Upr), -3.45% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>310 - 329</td>
<td>320</td>
<td>2.74% (Upr), -3.23% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>330 - 349</td>
<td>340</td>
<td>2.58% (Upr), -3.03% (Lwr)</td>
<td>9mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>350 - 379</td>
<td>360</td>
<td>2.43% (Upr), -2.86% (Lwr)</td>
<td>19mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>380 - 419</td>
<td>400</td>
<td>4.53% (Upr), -5.26% (Lwr)</td>
<td>19mg (Upr), -20mg (Lwr)</td>
</tr>
<tr>
<td>420 - 459</td>
<td>440</td>
<td>4.14% (Upr), -4.76% (Lwr)</td>
<td>19mg (Upr), -20mg (Lwr)</td>
</tr>
<tr>
<td>460 - 499</td>
<td>480</td>
<td>3.81% (Upr), -4.35% (Lwr)</td>
<td>19mg (Upr), -20mg (Lwr)</td>
</tr>
<tr>
<td>500 - 539</td>
<td>520</td>
<td>3.53% (Upr), -4.00% (Lwr)</td>
<td>19mg (Upr), -20mg (Lwr)</td>
</tr>
<tr>
<td>540 - 579</td>
<td>560</td>
<td>3.28% (Upr), -3.70% (Lwr)</td>
<td>19mg (Upr), -20mg (Lwr)</td>
</tr>
<tr>
<td>580 - 625</td>
<td>600</td>
<td>4.00% (Upr), -3.45% (Lwr)</td>
<td>25mg (Upr), -20mg (Lwr)</td>
</tr>
<tr>
<td>626 - 675</td>
<td>650</td>
<td>3.70% (Upr), -3.83% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>676 - 725</td>
<td>700</td>
<td>3.45% (Upr), -3.55% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>726 - 775</td>
<td>750</td>
<td>3.23% (Upr), -3.31% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>776 - 825</td>
<td>800</td>
<td>3.03% (Upr), -3.09% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>826 - 875</td>
<td>850</td>
<td>2.86% (Upr), -2.91% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
</tr>
</tbody>
</table>

This information is valid only on the day of printing, for any updates please check [www.hse.ie/nccpdosebanding](http://www.hse.ie/nccpdosebanding)
METHOTREXATE IV INFUSION (Version 1) continued

<p>| 876 - 925 | 900 | 2.70% (Upr)<em>, -2.74% (Lwr) | 25mg (Upr), -24mg (Lwr) |
| 926 - 975 | 950 | 2.56% (Upr)</em>, -2.59% (Lwr) | 25mg (Upr), -24mg (Lwr) |
| 976 - 1050 | 1000 | 4.76% (Upr)<em>, -2.46% (Lwr) | 50mg (Upr), -24mg (Lwr) |
| 1051 - 1150 | 1100 | 4.35% (Upr)</em>, -4.66% (Lwr) | 50mg (Upr), -49mg (Lwr) |
| 1151 - 1250 | 1200 | 4.00% (Upr)<em>, -4.26% (Lwr) | 50mg (Upr), -49mg (Lwr) |
| 1251 - 1350 | 1300 | 3.70% (Upr)</em>, -3.92% (Lwr) | 50mg (Upr), -49mg (Lwr) |
| 1351 - 1470 | 1400 | 4.76% (Upr)<em>, -3.63% (Lwr) | 70mg (Upr), -49mg (Lwr) |
| 1471 - 1600 | 1540 | 3.75% (Upr)</em>, -4.69% (Lwr) | 60mg (Upr), -69mg (Lwr) |
| 1601 - 1740 | 1680 | 3.45% (Upr)<em>, -4.93% (Lwr) | 60mg (Upr), -79mg (Lwr) |
| 1741 - 1900 | 1820 | 4.21% (Upr)</em>, -4.54% (Lwr) | 80mg (Upr), -79mg (Lwr) |
| 1901 - 2100 | 2000 | 4.76% (Upr)<em>, -5.21% (Lwr) | 100mg (Upr), -99mg (Lwr) |
| 2101 - 2300 | 2200 | 4.35% (Upr)</em>, -4.71% (Lwr) | 100mg (Upr), -99mg (Lwr) |
| 2301 - 2520 | 2400 | 4.76% (Upr)<em>, -4.30% (Lwr) | 120mg (Upr), -99mg (Lwr) |
| 2521 - 2760 | 2640 | 4.35% (Upr)</em>, -4.72% (Lwr) | 120mg (Upr), -119mg (Lwr) |
| 2761 - 3040 | 2900 | 4.61% (Upr)<em>, -5.03% (Lwr) | 140mg (Upr), -139mg (Lwr) |
| 3041 - 3350 | 3200 | 4.48% (Upr)</em>, -5.23% (Lwr) | 150mg (Upr), -159mg (Lwr) |
| 3351 - 3650 | 3500 | 4.11% (Upr)<em>, -4.45% (Lwr) | 150mg (Upr), -149mg (Lwr) |
| 3651 - 3990 | 3800 | 4.76% (Upr)</em>, -4.08% (Lwr) | 190mg (Upr), -149mg (Lwr) |
| 3991 - 4400 | 4200 | 4.55% (Upr)<em>, -5.24% (Lwr) | 200mg (Upr), -209mg (Lwr) |
| 4401 - 4800 | 4600 | 4.17% (Upr)</em>, -4.52% (Lwr) | 200mg (Upr), -199mg (Lwr) |
| 4801 - 5250 | 5000 | 4.76% (Upr)<em>, -4.14% (Lwr) | 250mg (Upr), -199mg (Lwr) |
| 5251 - 5750 | 5500 | 4.35% (Upr)</em>, -4.74% (Lwr) | 250mg (Upr), -249mg (Lwr) |
| 5751 - 6250 | 6000 | 4.00% (Upr)<em>, -4.33% (Lwr) | 250mg (Upr), -249mg (Lwr) |
| 6251 - 6750 | 6500 | 3.70% (Upr)</em>, -3.98% (Lwr) | 250mg (Upr), -249mg (Lwr) |
| 6751 - 7250 | 7000 | 3.45% (Upr)<em>, -3.69% (Lwr) | 250mg (Upr), -249mg (Lwr) |
| 7251 - 7750 | 7500 | 3.23% (Upr)</em>, -3.43% (Lwr) | 250mg (Upr), -249mg (Lwr) |
| 7751 - 8250 | 8000 | 3.03% (Upr)<em>, -3.21% (Lwr) | 250mg (Upr), -249mg (Lwr) |
| 8251 - 8750 | 8500 | 2.86% (Upr)</em>, -3.02% (Lwr) | 250mg (Upr), -249mg (Lwr) |
| 8751 - 9250 | 9000 | 2.70% (Upr)<em>, -2.85% (Lwr) | 250mg (Upr), -249mg (Lwr) |
| 9251 - 9750 | 9500 | 2.56% (Upr)</em>, -2.69% (Lwr) | 250mg (Upr), -249mg (Lwr) |
| 9751 - 10500 | 10000 | 4.76% (Upr)<em>, -2.55% (Lwr) | 500mg (Upr), -249mg (Lwr) |
| 10501 - 11500 | 11000 | 4.35% (Upr)</em>, -4.75% (Lwr) | 500mg (Upr), -499mg (Lwr) |</p>
<table>
<thead>
<tr>
<th>NCCP Dose Banding Tables</th>
<th>Published: July 2017</th>
<th>Version: 2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Review: July 2019</td>
<td></td>
</tr>
</tbody>
</table>
| This information is valid only on the day of printing, for any updates please check [www.hse.ie/nccpdosebanding](http://www.hse.ie/nccpdosebanding)

**METHOTREXATE IV INFUSION (Version 1) continued**

<table>
<thead>
<tr>
<th>Range</th>
<th>Unit</th>
<th>Upper Banding %</th>
<th>Lower Banding %</th>
<th>Dose (Upr)</th>
<th>Dose (Lwr)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11501 - 12500</td>
<td>12000</td>
<td>4.00% (Upr)*, -4.34% (Lwr)</td>
<td>500mg (Upr), -499mg (Lwr)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12501 - 13500</td>
<td>13000</td>
<td>3.70% (Upr)*, -3.99% (Lwr)</td>
<td>500mg (Upr), -499mg (Lwr)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13501 - 14500</td>
<td>14000</td>
<td>3.45% (Upr)*, -3.70% (Lwr)</td>
<td>500mg (Upr), -499mg (Lwr)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14501 - 15500</td>
<td>15000</td>
<td>3.23% (Upr)*, -3.44% (Lwr)</td>
<td>500mg (Upr), -499mg (Lwr)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15501 - 16500</td>
<td>16000</td>
<td>3.03% (Upr)*, -3.22% (Lwr)</td>
<td>500mg (Upr), -499mg (Lwr)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16501 - 17500</td>
<td>17000</td>
<td>2.86% (Upr)*, -3.02% (Lwr)</td>
<td>500mg (Upr), -499mg (Lwr)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17501 - 18500</td>
<td>18000</td>
<td>2.70% (Upr)*, -2.85% (Lwr)</td>
<td>500mg (Upr), -499mg (Lwr)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18501 - 19500</td>
<td>19000</td>
<td>2.56% (Upr)*, -2.70% (Lwr)</td>
<td>500mg (Upr), -499mg (Lwr)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19501 - 21000</td>
<td>20000</td>
<td>4.76% (Upr)*, -2.56% (Lwr)</td>
<td>1000mg (Upr), -499mg (Lwr)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>21001 - 23000</td>
<td>22000</td>
<td>4.35% (Upr)*, -4.76% (Lwr)</td>
<td>1000mg (Upr), -999mg (Lwr)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>23001 - 25000</td>
<td>24000</td>
<td>4.00% (Upr)*, -4.34% (Lwr)</td>
<td>1000mg (Upr), -999mg (Lwr)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
OXALIPLATIN IV INFUSION (Version 2):
The dose bands used in this table are constructed based on a 5mg/ml concentration of oxaliplatin

<table>
<thead>
<tr>
<th>Dose Range (mg)</th>
<th>Banded Dose (mg)</th>
<th>Maximum variation range (%)</th>
<th>Maximum variation range (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>115 - 125</td>
<td>120</td>
<td>4.00% (Upr)**, -4.35% (Lwr)</td>
<td>5mg (Upr), -5mg (Lwr)</td>
</tr>
<tr>
<td>126 - 135</td>
<td>130</td>
<td>3.70% (Upr)**, -3.17% (Lwr)</td>
<td>5mg (Upr), -4mg (Lwr)</td>
</tr>
<tr>
<td>136 - 145</td>
<td>140</td>
<td>3.45% (Upr)**, -2.94% (Lwr)</td>
<td>5mg (Upr), -4mg (Lwr)</td>
</tr>
<tr>
<td>146 - 155</td>
<td>150</td>
<td>3.23% (Upr)**, -2.74% (Lwr)</td>
<td>5mg (Upr), -4mg (Lwr)</td>
</tr>
<tr>
<td>156 - 165</td>
<td>160</td>
<td>3.03% (Upr)**, -2.56% (Lwr)</td>
<td>5mg (Upr), -4mg (Lwr)</td>
</tr>
<tr>
<td>166 - 175</td>
<td>170</td>
<td>2.86% (Upr)**, -2.41% (Lwr)</td>
<td>5mg (Upr), -4mg (Lwr)</td>
</tr>
<tr>
<td>176 - 190</td>
<td>185</td>
<td>2.63% (Upr)**, 5.11% (Lwr)</td>
<td>5mg (Upr), -9mg (Lwr)</td>
</tr>
<tr>
<td>191 - 210</td>
<td>200</td>
<td>4.76% (Upr)**, -4.71% (Lwr)</td>
<td>10mg (Upr), -9mg (Lwr)</td>
</tr>
<tr>
<td>211 - 230</td>
<td>220</td>
<td>4.35% (Upr)**, -4.27% (Lwr)</td>
<td>10mg (Upr), -9mg (Lwr)</td>
</tr>
<tr>
<td>231 - 250</td>
<td>240</td>
<td>4.00% (Upr)**, -3.90% (Lwr)</td>
<td>10mg (Upr), -9mg (Lwr)</td>
</tr>
<tr>
<td>251 - 270</td>
<td>260</td>
<td>3.70% (Upr)**, -3.59% (Lwr)</td>
<td>10mg (Upr), -9mg (Lwr)</td>
</tr>
<tr>
<td>271 - 290</td>
<td>280</td>
<td>3.45% (Upr)**, -3.32% (Lwr)</td>
<td>10mg (Upr), -9mg (Lwr)</td>
</tr>
<tr>
<td>291 - 310</td>
<td>300</td>
<td>3.23% (Upr)**, -3.09% (Lwr)</td>
<td>10mg (Upr), -9mg (Lwr)</td>
</tr>
</tbody>
</table>
PACLITAXEL IV INFUSION (Version 2):
The dose bands used in this table are constructed based on a 6mg/ml concentration of paclitaxel.
Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

<table>
<thead>
<tr>
<th>Dose Range (mg)</th>
<th>Banded Dose (mg)</th>
<th>Maximum variation range (%)</th>
<th>Maximum variation range (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>57 - 63</td>
<td>60</td>
<td>4.76% (Upr)*, -5.26% (Lwr)</td>
<td>3mg (Upr), -3mg (Lwr)</td>
</tr>
<tr>
<td>64 - 69</td>
<td>66</td>
<td>4.35% (Upr)*, -3.13% (Lwr)</td>
<td>3mg (Upr), -2mg (Lwr)</td>
</tr>
<tr>
<td>70 - 75</td>
<td>72</td>
<td>4.00% (Upr)*, -2.86% (Lwr)</td>
<td>3mg (Upr), -2mg (Lwr)</td>
</tr>
<tr>
<td>76 - 81</td>
<td>78</td>
<td>3.70% (Upr)*, -2.63% (Lwr)</td>
<td>3mg (Upr), -2mg (Lwr)</td>
</tr>
<tr>
<td>82 - 86</td>
<td>84</td>
<td>2.33% (Upr)*, -2.44% (Lwr)</td>
<td>2mg (Upr), -2mg (Lwr)</td>
</tr>
<tr>
<td>87 - 93</td>
<td>90</td>
<td>3.23% (Upr)*, -3.45% (Lwr)</td>
<td>3mg (Upr), -3mg (Lwr)</td>
</tr>
<tr>
<td>94 - 99</td>
<td>96</td>
<td>3.03% (Upr)*, -2.13% (Lwr)</td>
<td>3mg (Upr), -2mg (Lwr)</td>
</tr>
<tr>
<td>100 - 105</td>
<td>102</td>
<td>2.86% (Upr)*, -2.00% (Lwr)</td>
<td>3mg (Upr), -2mg (Lwr)</td>
</tr>
<tr>
<td>106 - 113</td>
<td>108</td>
<td>4.42% (Upr)*, -1.89% (Lwr)</td>
<td>5mg (Upr), -2mg (Lwr)</td>
</tr>
<tr>
<td>114 - 126</td>
<td>120</td>
<td>4.76% (Upr)*, 5.26% (Lwr)</td>
<td>6mg (Upr), -6mg (Lwr)</td>
</tr>
<tr>
<td>127 - 138</td>
<td>132</td>
<td>4.35% (Upr)*, -3.94% (Lwr)</td>
<td>6mg (Upr), -5mg (Lwr)</td>
</tr>
<tr>
<td>139 - 150</td>
<td>144</td>
<td>4.00% (Upr)*, -3.60% (Lwr)</td>
<td>6mg (Upr), -5mg (Lwr)</td>
</tr>
<tr>
<td>151 - 162</td>
<td>156</td>
<td>3.70% (Upr)*, -3.31% (Lwr)</td>
<td>6mg (Upr), -5mg (Lwr)</td>
</tr>
<tr>
<td>163 - 174</td>
<td>168</td>
<td>3.45% (Upr)*, -3.07% (Lwr)</td>
<td>6mg (Upr), -5mg (Lwr)</td>
</tr>
<tr>
<td>175 - 186</td>
<td>180</td>
<td>3.23% (Upr)*, -2.86% (Lwr)</td>
<td>6mg (Upr), -5mg (Lwr)</td>
</tr>
<tr>
<td>187 - 198</td>
<td>192</td>
<td>3.03% (Upr)*, -2.67% (Lwr)</td>
<td>6mg (Upr), -5mg (Lwr)</td>
</tr>
<tr>
<td>199 - 210</td>
<td>204</td>
<td>2.86% (Upr)*, -2.51% (Lwr)</td>
<td>6mg (Upr), -5mg (Lwr)</td>
</tr>
<tr>
<td>211 - 222</td>
<td>216</td>
<td>2.70% (Upr)*, -2.37% (Lwr)</td>
<td>6mg (Upr), -5mg (Lwr)</td>
</tr>
<tr>
<td>223 - 246</td>
<td>234</td>
<td>4.88% (Upr)*, -4.93% (Lwr)</td>
<td>12mg (Upr), -11mg (Lwr)</td>
</tr>
<tr>
<td>247 - 264</td>
<td>252</td>
<td>4.55% (Upr)*, -2.02% (Lwr)</td>
<td>12mg (Upr), -5mg (Lwr)</td>
</tr>
<tr>
<td>265 - 282</td>
<td>270</td>
<td>4.26% (Upr)*, -1.89% (Lwr)</td>
<td>12mg (Upr), -5mg (Lwr)</td>
</tr>
<tr>
<td>283 - 306</td>
<td>294</td>
<td>3.92% (Upr)*, -3.89% (Lwr)</td>
<td>12mg (Upr), -11mg (Lwr)</td>
</tr>
<tr>
<td>307 - 330</td>
<td>318</td>
<td>3.64% (Upr)*, -3.58% (Lwr)</td>
<td>12mg (Upr), -11mg (Lwr)</td>
</tr>
<tr>
<td>331 - 354</td>
<td>342</td>
<td>3.39% (Upr)*, -3.32% (Lwr)</td>
<td>12mg (Upr), -11mg (Lwr)</td>
</tr>
<tr>
<td>355 - 378</td>
<td>366</td>
<td>3.17% (Upr)*, -3.10% (Lwr)</td>
<td>12mg (Upr), -11mg (Lwr)</td>
</tr>
<tr>
<td>379 - 402</td>
<td>390</td>
<td>2.99% (Upr)*, -2.90% (Lwr)</td>
<td>12mg (Upr), -11mg (Lwr)</td>
</tr>
<tr>
<td>403 - 426</td>
<td>414</td>
<td>2.82% (Upr)*, -2.73% (Lwr)</td>
<td>12mg (Upr), -11mg (Lwr)</td>
</tr>
<tr>
<td>427 - 450</td>
<td>438</td>
<td>2.67% (Upr)*, -2.58% (Lwr)</td>
<td>12mg (Upr), -11mg (Lwr)</td>
</tr>
</tbody>
</table>
PEMBROLIZUMAB IV INFUSION (Version 1):
The dose bands used in this table are constructed based on a 25mg/ml concentration of pembrolizumab.
Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

<table>
<thead>
<tr>
<th>Dose Range (mg)</th>
<th>Banded Dose (mg)</th>
<th>Maximum variation range (%)</th>
<th>Maximum variation range (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>58 - 62</td>
<td>60</td>
<td>3.23% (Upr)*, -3.45% (Lwr)</td>
<td>2mg (Upr), -2mg (Lwr)</td>
</tr>
<tr>
<td>63 - 67</td>
<td>65</td>
<td>2.99% (Upr)*, -3.17% (Lwr)</td>
<td>2mg (Upr), -2mg (Lwr)</td>
</tr>
<tr>
<td>68 - 72</td>
<td>70</td>
<td>2.78% (Upr)*, -2.94% (Lwr)</td>
<td>2mg (Upr), -2mg (Lwr)</td>
</tr>
<tr>
<td>73 - 77</td>
<td>75</td>
<td>2.60% (Upr)*, -2.74% (Lwr)</td>
<td>2mg (Upr), -2mg (Lwr)</td>
</tr>
<tr>
<td>78 - 82</td>
<td>80</td>
<td>2.44% (Upr)*, -2.56% (Lwr)</td>
<td>2mg (Upr), -2mg (Lwr)</td>
</tr>
<tr>
<td>83 - 87</td>
<td>85</td>
<td>2.30% (Upr)*, -2.41% (Lwr)</td>
<td>2mg (Upr), -2mg (Lwr)</td>
</tr>
<tr>
<td>88 - 92</td>
<td>90</td>
<td>2.17% (Upr)*, -2.27% (Lwr)</td>
<td>2mg (Upr), -2mg (Lwr)</td>
</tr>
<tr>
<td>93 - 97</td>
<td>95</td>
<td>2.06% (Upr)*, -2.15% (Lwr)</td>
<td>2mg (Upr), -2mg (Lwr)</td>
</tr>
<tr>
<td>98 - 105</td>
<td>100</td>
<td>4.76% (Upr)*, -2.04% (Lwr)</td>
<td>5mg (Upr), -2mg (Lwr)</td>
</tr>
<tr>
<td>106 - 115</td>
<td>110</td>
<td>4.35% (Upr)*, -3.77% (Lwr)</td>
<td>5mg (Upr), -4mg (Lwr)</td>
</tr>
<tr>
<td>116 - 125</td>
<td>120</td>
<td>4.00% (Upr)*, -3.45% (Lwr)</td>
<td>5mg (Upr), -4mg (Lwr)</td>
</tr>
<tr>
<td>126 - 135</td>
<td>130</td>
<td>3.70% (Upr)*, -3.17% (Lwr)</td>
<td>5mg (Upr), -4mg (Lwr)</td>
</tr>
<tr>
<td>136 - 145</td>
<td>140</td>
<td>3.45% (Upr)*, -2.94% (Lwr)</td>
<td>5mg (Upr), -4mg (Lwr)</td>
</tr>
<tr>
<td>146 - 157</td>
<td>150</td>
<td>4.46% (Upr)*, -2.74% (Lwr)</td>
<td>7mg (Upr), -4mg (Lwr)</td>
</tr>
<tr>
<td>158 - 174</td>
<td>165</td>
<td>6.17% (Upr)*, -4.43% (Lwr)</td>
<td>9mg (Upr), -7mg (Lwr)</td>
</tr>
<tr>
<td>175 - 189</td>
<td>180</td>
<td>4.76% (Upr)*, -2.86% (Lwr)</td>
<td>9mg (Upr), -5mg (Lwr)</td>
</tr>
<tr>
<td>190 - 207</td>
<td>200</td>
<td>3.38% (Upr)*, 5.26% (Lwr)</td>
<td>7mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>208 - 222</td>
<td>215</td>
<td>3.15% (Upr)*, -3.37% (Lwr)</td>
<td>7mg (Upr), -7mg (Lwr)</td>
</tr>
<tr>
<td>223 - 239</td>
<td>230</td>
<td>3.77% (Upr)*, -3.14% (Lwr)</td>
<td>9mg (Upr), -7mg (Lwr)</td>
</tr>
<tr>
<td>240 - 263</td>
<td>250</td>
<td>4.94% (Upr)*, -4.17% (Lwr)</td>
<td>13mg (Upr), -10mg (Lwr)</td>
</tr>
</tbody>
</table>
**PEMETREXED IV INFUSION (Version 1):**
The dose bands used in this table are constructed based on a 25mg/ml concentration of pemetrexed

<table>
<thead>
<tr>
<th>Dose Range (mg)</th>
<th>Banded Dose (mg)</th>
<th>Maximum variation range (%)</th>
<th>Maximum variation range (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>475-524</td>
<td>500</td>
<td>4.58% (Upr)*, 5.26% (Lwr)</td>
<td>24mg (Upr), -25mg (Lwr)</td>
</tr>
<tr>
<td>525-574</td>
<td>550</td>
<td>4.18% (Upr)*, -4.76% (Lwr)</td>
<td>24mg (Upr), -25mg (Lwr)</td>
</tr>
<tr>
<td>575-624</td>
<td>600</td>
<td>3.85% (Upr)*, -4.35% (Lwr)</td>
<td>24mg (Upr), -25mg (Lwr)</td>
</tr>
<tr>
<td>625-674</td>
<td>650</td>
<td>3.56% (Upr)*, -4.00% (Lwr)</td>
<td>24mg (Upr), -25mg (Lwr)</td>
</tr>
<tr>
<td>675-724</td>
<td>700</td>
<td>3.31% (Upr)*, -3.70% (Lwr)</td>
<td>24mg (Upr), -25mg (Lwr)</td>
</tr>
<tr>
<td>725-785</td>
<td>750</td>
<td>4.46% (Upr)*, -3.45% (Lwr)</td>
<td>35mg (Upr), -25mg (Lwr)</td>
</tr>
<tr>
<td>786-859</td>
<td>825</td>
<td>3.96% (Upr)*, -4.96% (Lwr)</td>
<td>34mg (Upr), -39mg (Lwr)</td>
</tr>
<tr>
<td>860-949</td>
<td>900</td>
<td>5.16% (Upr)*, -4.65% (Lwr)</td>
<td>49mg (Upr), -40mg (Lwr)</td>
</tr>
<tr>
<td>950-1049</td>
<td>1000</td>
<td>4.67% (Upr)*, 5.26% (Lwr)</td>
<td>49mg (Upr), -50mg (Lwr)</td>
</tr>
<tr>
<td>1050-1149</td>
<td>1100</td>
<td>4.26% (Upr)*, -4.76% (Lwr)</td>
<td>49mg (Upr), -50mg (Lwr)</td>
</tr>
<tr>
<td>1150-1249</td>
<td>1200</td>
<td>3.92% (Upr)*, -4.35% (Lwr)</td>
<td>49mg (Upr), -50mg (Lwr)</td>
</tr>
</tbody>
</table>

This information is valid only on the day of printing, for any updates please check [www.hse.ie/nccpdosebanding](http://www.hse.ie/nccpdosebanding)
VINORELBINE IV INFUSION (Version 1):
The dose bands used in this table are constructed based on a 10mg/ml concentration of vinorelbine
Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume

<table>
<thead>
<tr>
<th>Dose Range (mg)</th>
<th>Banded Dose (mg)</th>
<th>Maximum variation range (%)</th>
<th>Maximum variation range (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>19 - 21</td>
<td>20</td>
<td>4.76% (Upr)*, 5.26% (Lwr)</td>
<td>1mg (Upr), -1mg (Lwr)</td>
</tr>
<tr>
<td>21.1 - 23</td>
<td>22</td>
<td>4.35% (Upr)*, -4.27% (Lwr)</td>
<td>1mg (Upr), -0.9mg (Lwr)</td>
</tr>
<tr>
<td>23.1 - 25</td>
<td>24</td>
<td>4.00% (Upr)*, -3.90% (Lwr)</td>
<td>1mg (Upr), -0.9mg (Lwr)</td>
</tr>
<tr>
<td>25.1 - 27</td>
<td>26</td>
<td>3.70% (Upr)*, -3.59% (Lwr)</td>
<td>1mg (Upr), -0.9mg (Lwr)</td>
</tr>
<tr>
<td>27.1 - 29</td>
<td>28</td>
<td>3.45% (Upr)*, -3.32% (Lwr)</td>
<td>1mg (Upr), -0.9mg (Lwr)</td>
</tr>
<tr>
<td>29.1 - 32</td>
<td>30</td>
<td>3.25% (Upr)*, -3.09% (Lwr)</td>
<td>2mg (Upr), -0.9mg (Lwr)</td>
</tr>
<tr>
<td>33 - 36</td>
<td>34</td>
<td>3.06% (Upr)*, -3.03% (Lwr)</td>
<td>2mg (Upr), -1mg (Lwr)</td>
</tr>
<tr>
<td>37 - 40</td>
<td>38</td>
<td>5.00% (Upr)*, -2.70% (Lwr)</td>
<td>2mg (Upr), -1mg (Lwr)</td>
</tr>
<tr>
<td>41 - 44</td>
<td>42</td>
<td>4.55% (Upr)*, -2.44% (Lwr)</td>
<td>2mg (Upr), -1mg (Lwr)</td>
</tr>
<tr>
<td>45 - 48</td>
<td>46</td>
<td>4.17% (Upr)*, -2.22% (Lwr)</td>
<td>2mg (Upr), -1mg (Lwr)</td>
</tr>
<tr>
<td>49 - 51</td>
<td>50</td>
<td>1.96% (Upr)*, -2.04% (Lwr)</td>
<td>1mg (Upr), -1mg (Lwr)</td>
</tr>
<tr>
<td>52 - 57</td>
<td>54</td>
<td>5.26% (Upr)*, -3.85% (Lwr)</td>
<td>3mg (Upr), -2mg (Lwr)</td>
</tr>
<tr>
<td>58 - 63</td>
<td>60</td>
<td>4.76% (Upr)*, -3.45% (Lwr)</td>
<td>3mg (Upr), -2mg (Lwr)</td>
</tr>
</tbody>
</table>

This information is valid only on the day of printing, for any updates please check [www.hse.ie/nccpdosebanding](http://www.hse.ie/nccpdosebanding)
DOSE BANDING TABLES – MONOCLONALS FOR INTRAVENOUS INFUSION

**MONOCLONALS - BEVACIZUMAB IV INFUSION (Version 2):**
The dose bands used in this table are constructed based on a 25mg/ml concentration of bevacizumab
Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume

<table>
<thead>
<tr>
<th>Dose Range (mg)</th>
<th>Banded Dose (mg)</th>
<th>Maximum variation range (%)</th>
<th>Maximum variation range (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>190 - 211</td>
<td>200</td>
<td>5.21% (Upr)*, -5.26% (Lwr)</td>
<td>11mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>212 - 236</td>
<td>225</td>
<td>4.66% (Upr)*, -6.13% (Lwr)</td>
<td>11mg (Upr), -13mg (Lwr)</td>
</tr>
<tr>
<td>237 - 261</td>
<td>250</td>
<td>4.21% (Upr)*, -5.49% (Lwr)</td>
<td>11mg (Upr), -13mg (Lwr)</td>
</tr>
<tr>
<td>262 - 286</td>
<td>275</td>
<td>3.85% (Upr)*, -4.96% (Lwr)</td>
<td>11mg (Upr), -13mg (Lwr)</td>
</tr>
<tr>
<td>287 - 311</td>
<td>300</td>
<td>3.54% (Upr)*, -4.53% (Lwr)</td>
<td>11mg (Upr), -13mg (Lwr)</td>
</tr>
<tr>
<td>312 - 336</td>
<td>325</td>
<td>3.27% (Upr)*, -4.17% (Lwr)</td>
<td>11mg (Upr), -13mg (Lwr)</td>
</tr>
<tr>
<td>337 - 361</td>
<td>350</td>
<td>3.05% (Upr)*, -3.86% (Lwr)</td>
<td>11mg (Upr), -13mg (Lwr)</td>
</tr>
<tr>
<td>362 - 386</td>
<td>375</td>
<td>2.85% (Upr)*, -3.59% (Lwr)</td>
<td>11mg (Upr), -13mg (Lwr)</td>
</tr>
<tr>
<td>387 - 411</td>
<td>400</td>
<td>2.68% (Upr)*, -3.36% (Lwr)</td>
<td>11mg (Upr), -13mg (Lwr)</td>
</tr>
<tr>
<td>412 - 436</td>
<td>425</td>
<td>2.52% (Upr)*, -3.16% (Lwr)</td>
<td>11mg (Upr), -13mg (Lwr)</td>
</tr>
<tr>
<td>437 - 461</td>
<td>450</td>
<td>2.39% (Upr)*, -2.97% (Lwr)</td>
<td>11mg (Upr), -13mg (Lwr)</td>
</tr>
<tr>
<td>462 - 486</td>
<td>475</td>
<td>2.26% (Upr)*, -2.81% (Lwr)</td>
<td>11mg (Upr), -13mg (Lwr)</td>
</tr>
<tr>
<td>487 - 525</td>
<td>500</td>
<td>4.76% (Upr)*, -2.67% (Lwr)</td>
<td>25mg (Upr), -13mg (Lwr)</td>
</tr>
<tr>
<td>526 - 575</td>
<td>550</td>
<td>4.35% (Upr)*, -4.56% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>576 - 625</td>
<td>600</td>
<td>4.00% (Upr)*, -4.17% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>626 - 675</td>
<td>650</td>
<td>3.70% (Upr)*, -3.83% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>676 - 725</td>
<td>700</td>
<td>3.45% (Upr)*, -3.55% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>726 - 775</td>
<td>750</td>
<td>3.23% (Upr)*, -3.31% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>776 - 825</td>
<td>800</td>
<td>3.03% (Upr)*, -3.09% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>826 - 875</td>
<td>850</td>
<td>2.86% (Upr)*, -2.91% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>876 - 925</td>
<td>900</td>
<td>2.70% (Upr)*, -2.74% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>926 - 975</td>
<td>950</td>
<td>2.56% (Upr)*, -2.59% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>976 - 1050</td>
<td>1000</td>
<td>4.76% (Upr)*, -2.46% (Lwr)</td>
<td>50mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>1051 - 1150</td>
<td>1100</td>
<td>4.35% (Upr)*, -4.66% (Lwr)</td>
<td>50mg (Upr), -49mg (Lwr)</td>
</tr>
<tr>
<td>1151 - 1250</td>
<td>1200</td>
<td>4.00% (Upr)*, -4.26% (Lwr)</td>
<td>50mg (Upr), -49mg (Lwr)</td>
</tr>
</tbody>
</table>
### BEVACIZUMAB IV INFUSION (Version 2) continued:

<table>
<thead>
<tr>
<th>Range</th>
<th>BEVACIZUMAB IV INFUSION (mg)</th>
<th>Upper Band (%)</th>
<th>Lower Band (%)</th>
<th>Upr mg</th>
<th>Lwr mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1251 - 1350</td>
<td>1300</td>
<td>3.70% (Upr)&quot; , -3.92% (Lwr)</td>
<td>50mg (Upr), -49mg (Lwr)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1351 - 1450</td>
<td>1400</td>
<td>3.45% (Upr)&quot; , -3.63% (Lwr)</td>
<td>50mg (Upr), -49mg (Lwr)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1451 - 1575</td>
<td>1500</td>
<td>4.76% (Upr)&quot; , -3.38% (Lwr)</td>
<td>75mg (Upr), -49mg (Lwr)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
MONOCLONALS – RITUXIMAB IV INFUSION (Version 2):
The dose bands used in this table are constructed based on a 10mg/ml concentration of rituximab.

<table>
<thead>
<tr>
<th>Dose Range (mg)</th>
<th>Banded Dose (mg)</th>
<th>Maximum variation range (%)</th>
<th>Maximum variation range (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>475 - 525</td>
<td>500</td>
<td>4.76% (Upr)*, -5.26% (Lwr)</td>
<td>25mg (Upr), -25mg (Lwr)</td>
</tr>
<tr>
<td>526 - 575</td>
<td>550</td>
<td>4.35% (Upr)*, -4.56% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>576 - 625</td>
<td>600</td>
<td>4.00% (Upr)*, -4.17% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>626 - 675</td>
<td>650</td>
<td>3.70% (Upr)*, -3.83% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>676 - 725</td>
<td>700</td>
<td>3.45% (Upr)*, -3.55% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>726 - 775</td>
<td>750</td>
<td>3.23% (Upr)*, -3.31% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>776 - 825</td>
<td>800</td>
<td>3.03% (Upr)*, -3.09% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>826 - 875</td>
<td>850</td>
<td>2.86% (Upr)*, -2.91% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>876 - 925</td>
<td>900</td>
<td>2.70% (Upr)*, -2.74% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>926 - 975</td>
<td>950</td>
<td>2.56% (Upr)*, -2.59% (Lwr)</td>
<td>25mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>976 - 1050</td>
<td>1000</td>
<td>4.76% (Upr)*, -2.46% (Lwr)</td>
<td>50mg (Upr), -24mg (Lwr)</td>
</tr>
<tr>
<td>1051 - 1150</td>
<td>1100</td>
<td>4.35% (Upr)*, -4.66% (Lwr)</td>
<td>50mg (Upr), -49mg (Lwr)</td>
</tr>
<tr>
<td>1151 - 1250</td>
<td>1200</td>
<td>4.00% (Upr)*, -4.26% (Lwr)</td>
<td>50mg (Upr), -49mg (Lwr)</td>
</tr>
<tr>
<td>1251 - 1350</td>
<td>1300</td>
<td>3.70% (Upr)*, -3.92% (Lwr)</td>
<td>50mg (Upr), -49mg (Lwr)</td>
</tr>
</tbody>
</table>
**MONOCLONALS - TRASTUZUMAB IV INFUSION** (Version 2):

The dose bands used in this table are constructed based on a 21mg/ml concentration of trastuzumab. Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

<table>
<thead>
<tr>
<th>Dose Range (mg)</th>
<th>Banded Dose (mg)</th>
<th>Maximum variation range (%)</th>
<th>Maximum variation range (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>95 - 115</td>
<td>105</td>
<td>8.70% (Upr)*, -10.53% (Lwr)</td>
<td>10mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>116 - 136</td>
<td>126</td>
<td>7.35% (Upr)*, -8.62% (Lwr)</td>
<td>10mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>137 - 157</td>
<td>147</td>
<td>6.37% (Upr)*, -7.30% (Lwr)</td>
<td>10mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>158 - 178</td>
<td>168</td>
<td>5.62% (Upr)*, -6.33% (Lwr)</td>
<td>10mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>179 - 199</td>
<td>189</td>
<td>5.03% (Upr)*, -5.59% (Lwr)</td>
<td>10mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>200 - 220</td>
<td>210</td>
<td>4.55% (Upr)*, -5.00% (Lwr)</td>
<td>10mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>221 - 241</td>
<td>231</td>
<td>4.15% (Upr)*, -4.52% (Lwr)</td>
<td>10mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>242 - 262</td>
<td>252</td>
<td>3.82% (Upr)*, -4.13% (Lwr)</td>
<td>10mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>263 - 283</td>
<td>273</td>
<td>3.53% (Upr)*, -3.80% (Lwr)</td>
<td>10mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>284 - 314</td>
<td>294</td>
<td>3.37% (Upr)*, -3.52% (Lwr)</td>
<td>20mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>315 - 346</td>
<td>336</td>
<td>2.89% (Upr)*, -2.67% (Lwr)</td>
<td>10mg (Upr), -21mg (Lwr)</td>
</tr>
<tr>
<td>347 - 367</td>
<td>357</td>
<td>2.72% (Upr)*, -2.88% (Lwr)</td>
<td>10mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>368 - 388</td>
<td>378</td>
<td>2.58% (Upr)*, -2.72% (Lwr)</td>
<td>10mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>389 - 419</td>
<td>399</td>
<td>2.47% (Upr)*, -2.57% (Lwr)</td>
<td>20mg (Upr), -10mg (Lwr)</td>
</tr>
<tr>
<td>420 - 461</td>
<td>441</td>
<td>4.34% (Upr)*, -5.00% (Lwr)</td>
<td>20mg (Upr), -21mg (Lwr)</td>
</tr>
<tr>
<td>462 - 514</td>
<td>483</td>
<td>3.93% (Upr)*, -4.55% (Lwr)</td>
<td>31mg (Upr), -21mg (Lwr)</td>
</tr>
<tr>
<td>515 - 566</td>
<td>546</td>
<td>3.53% (Upr)*, -6.02% (Lwr)</td>
<td>20mg (Upr), -31mg (Lwr)</td>
</tr>
<tr>
<td>567 - 618</td>
<td>588</td>
<td>4.85% (Upr)*, -3.70% (Lwr)</td>
<td>30mg (Upr), -21mg (Lwr)</td>
</tr>
<tr>
<td>619 - 683</td>
<td>651</td>
<td>4.69% (Upr)*, -5.17% (Lwr)</td>
<td>32mg (Upr), -32mg (Lwr)</td>
</tr>
<tr>
<td>684 - 755</td>
<td>714</td>
<td>5.43% (Upr)*, -4.39% (Lwr)</td>
<td>41mg (Upr), -30mg (Lwr)</td>
</tr>
<tr>
<td>756 - 839</td>
<td>798</td>
<td>4.89% (Upr)*, -5.56% (Lwr)</td>
<td>41mg (Upr), -42mg (Lwr)</td>
</tr>
<tr>
<td>840 - 933</td>
<td>882</td>
<td>5.47% (Upr)*, -5.00% (Lwr)</td>
<td>51mg (Upr), -42mg (Lwr)</td>
</tr>
<tr>
<td>934 - 1040</td>
<td>987</td>
<td>5.16% (Upr)*, -5.87% (Lwr)</td>
<td>53mg (Upr), -53mg (Lwr)</td>
</tr>
</tbody>
</table>
**MONOCLONALS – CETUXIMAB IV INFUSION** (Version 2):
The dose bands used in this table are constructed based on a 5mg/ml concentration of cetuximab.

<table>
<thead>
<tr>
<th>Dose Range (mg)</th>
<th>Banded Dose (mg)</th>
<th>Maximum variation range (%)</th>
<th>Maximum variation range (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>365 - 400</td>
<td>385</td>
<td>3.75% (Upr)*, -5.00% (Lwr)</td>
<td>15mg (Upr), -20mg (Lwr)</td>
</tr>
<tr>
<td>401 - 440</td>
<td>420</td>
<td>4.55% (Upr)*, -4.32% (Lwr)</td>
<td>20mg (Upr), -19mg (Lwr)</td>
</tr>
<tr>
<td>441 - 480</td>
<td>460</td>
<td>4.17% (Upr)*, -3.96% (Lwr)</td>
<td>20mg (Upr), -19mg (Lwr)</td>
</tr>
<tr>
<td>481 - 520</td>
<td>500</td>
<td>3.85% (Upr)*, -3.65% (Lwr)</td>
<td>20mg (Upr), -19mg (Lwr)</td>
</tr>
<tr>
<td>521 - 560</td>
<td>540</td>
<td>3.57% (Upr)*, -3.39% (Lwr)</td>
<td>20mg (Upr), -19mg (Lwr)</td>
</tr>
<tr>
<td>561 - 610</td>
<td>590</td>
<td>3.28% (Upr)*, -4.75% (Lwr)</td>
<td>20mg (Upr), -29mg (Lwr)</td>
</tr>
<tr>
<td>611 - 670</td>
<td>640</td>
<td>4.48% (Upr)*, -4.33% (Lwr)</td>
<td>30mg (Upr), -29mg (Lwr)</td>
</tr>
<tr>
<td>671 - 730</td>
<td>700</td>
<td>4.11% (Upr)*, -3.97% (Lwr)</td>
<td>30mg (Upr), -29mg (Lwr)</td>
</tr>
<tr>
<td>731 - 790</td>
<td>760</td>
<td>3.80% (Upr)*, -3.67% (Lwr)</td>
<td>30mg (Upr), -29mg (Lwr)</td>
</tr>
<tr>
<td>791 - 870</td>
<td>830</td>
<td>4.60% (Upr)*, -4.48% (Lwr)</td>
<td>40mg (Upr), -39mg (Lwr)</td>
</tr>
<tr>
<td>871 - 950</td>
<td>910</td>
<td>4.21% (Upr)*, -4.11% (Lwr)</td>
<td>40mg (Upr), -39mg (Lwr)</td>
</tr>
<tr>
<td>951 - 1050</td>
<td>1000</td>
<td>4.76% (Upr)*, -4.67% (Lwr)</td>
<td>50mg (Upr), -49mg (Lwr)</td>
</tr>
<tr>
<td>1051 - 1150</td>
<td>1100</td>
<td>4.35% (Upr)*, -4.26% (Lwr)</td>
<td>50mg (Upr), -49mg (Lwr)</td>
</tr>
<tr>
<td>1151 - 1250</td>
<td>1200</td>
<td>4.00% (Upr)*, -3.92% (Lwr)</td>
<td>50mg (Upr), -49mg (Lwr)</td>
</tr>
</tbody>
</table>
DOSE BANDING TABLES – ORAL ANTI-CANCER MEDICATIONS:

CAPECITABINE:
The dose bands used in this table are constructed based on combinations of 500mg and 150mg capecitabine tablets
Dose rounding has been applied to this table in order to facilitate the nearest measurable combination of tablets available.

<table>
<thead>
<tr>
<th>Dose Range (mg)</th>
<th>Banded Dose (mg)</th>
<th>Maximum variation range (%)</th>
<th>Maximum variation range (mg)</th>
<th>Suggested Tablets needed:</th>
</tr>
</thead>
<tbody>
<tr>
<td>750 - 850</td>
<td>800</td>
<td>5.88% (Upr)* , -5.88% (Lwr)</td>
<td>50mg (Upr), -50mg (Lwr)</td>
<td>1 x 500mg, 2 x 150mg</td>
</tr>
<tr>
<td>851 - 950</td>
<td>900</td>
<td>5.26% (Upr)* , -5.16% (Lwr)</td>
<td>50mg (Upr), -49mg (Lwr)</td>
<td>6 x 150mg</td>
</tr>
<tr>
<td>951 - 1075</td>
<td>1000</td>
<td>4.98% (Upr)* , -4.56% (Lwr)</td>
<td>75mg (Upr), -49mg (Lwr)</td>
<td>2 x 500mg</td>
</tr>
<tr>
<td>1075 - 1200</td>
<td>1150</td>
<td>4.17% (Upr)* , -5.25% (Lwr)</td>
<td>50mg (Upr), -75mg (Lwr)</td>
<td>2 x 500mg, 1 x 150mg</td>
</tr>
<tr>
<td>1201 - 1375</td>
<td>1300</td>
<td>5.45% (Upr)* , -7.20% (Lwr)</td>
<td>75mg (Upr), -99mg (Lwr)</td>
<td>2 x 500mg, 2 x 150mg</td>
</tr>
<tr>
<td>1376 - 1475</td>
<td>1450</td>
<td>1.69% (Upr)* , -5.02% (Lwr)</td>
<td>25mg (Upr), -74mg (Lwr)</td>
<td>2 x 500mg, 3 x 150mg</td>
</tr>
<tr>
<td>1476 - 1550</td>
<td>1500</td>
<td>3.23% (Upr)* , -1.55% (Lwr)</td>
<td>50mg (Upr), -24mg (Lwr)</td>
<td>3 x 500mg</td>
</tr>
<tr>
<td>1551 - 1700</td>
<td>1600</td>
<td>4.88% (Upr)* , -2.88% (Lwr)</td>
<td>100mg (Upr), -49mg (Lwr)</td>
<td>3 x 500mg, 1 x 150mg</td>
</tr>
<tr>
<td>1701 - 1900</td>
<td>1800</td>
<td>5.26% (Upr)* , -5.21% (Lwr)</td>
<td>100mg (Upr), -99mg (Lwr)</td>
<td>3 x 500mg, 2 x 150mg</td>
</tr>
<tr>
<td>1901 - 2075</td>
<td>2000</td>
<td>3.61% (Upr)* , -4.77% (Lwr)</td>
<td>75mg (Upr), -99mg (Lwr)</td>
<td>4 x 500mg</td>
</tr>
<tr>
<td>2076 - 2225</td>
<td>2150</td>
<td>3.37% (Upr)* , -3.33% (Lwr)</td>
<td>75mg (Upr), -74mg (Lwr)</td>
<td>4 x 500mg, 1 x 150mg</td>
</tr>
<tr>
<td>2226 - 2400</td>
<td>2300</td>
<td>4.17% (Upr)* , -3.08% (Lwr)</td>
<td>100mg (Upr), -74mg (Lwr)</td>
<td>4 x 500mg, 2 x 150mg</td>
</tr>
<tr>
<td>2401 - 2575</td>
<td>2500</td>
<td>2.91% (Upr)* , -3.84% (Lwr)</td>
<td>75mg (Upr), -99mg (Lwr)</td>
<td>5 x 500mg</td>
</tr>
<tr>
<td>2576 - 2775</td>
<td>2650</td>
<td>4.50% (Upr)* , -2.67% (Lwr)</td>
<td>125mg (Upr), -74mg (Lwr)</td>
<td>5 x 500mg, 1 x 150mg</td>
</tr>
<tr>
<td>2776 - 2900</td>
<td>2800</td>
<td>3.45% (Upr)* , -0.83% (Lwr)</td>
<td>100mg (Upr), -24mg (Lwr)</td>
<td>5 x 500mg, 2 x 150mg</td>
</tr>
</tbody>
</table>